[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 194
6. Tlemcani K, Levine D, Smith RV, Brandwein-Gensler M, Staffenberg DA, Garg MK, Shifteh K, Haigentz M Jr: Metastatic apocrine carcinoma of the scalp: prolonged response to systemic chemotherapy. J Clin Oncol; 2010 Aug 20;28(24):e412-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic apocrine carcinoma of the scalp: prolonged response to systemic chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / secondary. Scalp / pathology. Sweat Gland Neoplasms / drug therapy. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Alopecia / complications. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carboplatin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Drug Administration Schedule. Fatal Outcome. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Paclitaxel / administration & dosage. Young Adult

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


7. Somasundaram SK, Balasubramanian RK, Aref F, Karim S, Vashisht R: A rare and unusual case of bilateral, axillary, metachronous apocrine carcinoma. Int Surg; 2007 Nov-Dec;92(6):335-8
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare and unusual case of bilateral, axillary, metachronous apocrine carcinoma.
  • Apocrine carcinoma is a rare sweat gland neoplasm with very few cases reported in the published literature.
  • We report a case of primary axillary apocrine carcinoma with later recurrences in both axillae.
  • [MeSH-major] Adenocarcinoma / secondary. Apocrine Glands / pathology. Breast Neoplasms, Male / pathology. Neoplasms, Second Primary. Sweat Gland Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18402127.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


8. Vranic S, Tawfik O, Palazzo J, Bilalovic N, Eyzaguirre E, Lee LM, Adegboyega P, Hagenkord J, Gatalica Z: EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol; 2010 May;23(5):644-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast.
  • This study was undertaken to investigate epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2)/neu expression in a cohort of apocrine carcinomas of the breast with emphasis on the classification of the breast tumors with apocrine morphology.
  • In total, 55 breast carcinomas morphologically diagnosed as apocrine were evaluated for the steroid receptor expression profile characteristic of normal apocrine epithelium (androgen receptor positive/estrogen receptor (ER) negative/progesterone receptor (PR) negative), and for the expression of EGFR and Her-2/neu proteins, and the copy number ratios of the genes EGFR/CEP7 and HER-2/CEP17.
  • On the basis of the results of steroid receptors expression, 38 (69%) cases were classified as pure apocrine carcinoma (androgen receptor positive/ER negative/PR negative), whereas 17 (31%) were re-classified as apocrine-like carcinomas because they did not have the characteristic steroid receptor expression profile.
  • Her-2/neu overexpression was observed in 54% of the cases (57% pure apocrine carcinomas vs 47% apocrine-like carcinomas).
  • HER-2/neu gene amplification was demonstrated in 52% of all cases (54% pure apocrine carcinomas vs 46% apocrine-like carcinomas).
  • EGFR protein (scores 1 to 3+) was detected in 62% of all cases and was expressed in a higher proportion of pure apocrine carcinomas than in the apocrine-like carcinomas group (76 vs 29%, P=0.006).
  • In the pure apocrine carcinoma group, Her-2/neu and EGFR protein expression were inversely correlated (P=0.006, r=-0.499).
  • EGFR gene amplification was observed in two pure apocrine carcinomas and one apocrine-like carcinoma.
  • Polysomy 7 was commonly present in pure apocrine carcinomas (61 vs 27% of apocrine-like carcinomas; P=0.083) and showed a weak positive correlation with EGFR protein expression (P=0.025, r=0.326).
  • Our study showed that apocrine breast carcinomas are molecularly diverse group of carcinomas.
  • Strictly defined pure apocrine carcinomas are either HER-2-overexpressing breast carcinomas or triple-negative breast carcinomas, whereas apocrine-like carcinomas predominantly belong to the luminal phenotype.
  • Pure apocrine carcinomas show consistent overexpression of either EGFR or HER-2/neu, which could have significant therapeutic implications.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20208479.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Steroid; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


9. Ruiz-Villaverde R, Martinez FE, Luque Barona RJ, Sanz Trelles A: Primary cutaneous cribriform apocrine carcinoma on a typical location. Eur J Dermatol; 2010 Nov-Dec;20(6):832-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous cribriform apocrine carcinoma on a typical location.
  • [MeSH-major] Facial Neoplasms / pathology. Skin Neoplasms / pathology. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20923754.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  •  go-up   go-down


10. Fernandez-Flores A: Podoplanin immunostaining in cutaneous apocrine carcinoma and in cutaneous metastasis from the breast. Appl Immunohistochem Mol Morphol; 2010 Dec;18(6):573-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Podoplanin immunostaining in cutaneous apocrine carcinoma and in cutaneous metastasis from the breast.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20697264.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / PDPN protein, human; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


11. Jayaram G, Yaccob RB, Yip CH: Apocrine carcinoma of the breast diagnosed on fine needle aspiration cytology. Acta Cytol; 2007 Jul-Aug;51(4):664-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine carcinoma of the breast diagnosed on fine needle aspiration cytology.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17718149.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  •  go-up   go-down


12. Misago N, Ohkawa T, Narisawa Y: An unusual apocrine carcinoma on the forehead. Am J Dermatopathol; 2007 Aug;29(4):404-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual apocrine carcinoma on the forehead.
  • We herein report an unusual case of apocrine carcinoma on the forehead.
  • The lesion was formed by the anastomosis of numerous tubular structures with widespread decapitation secretion, thus demonstrating apocrine differentiation.
  • However, we observed some unusual histopathologic features that differed from those found in typical examples of apocrine ductal carcinoma, namely:.
  • We believe the present case is an apocrine ductal carcinoma, although it has a nodular appearance and basaloid cells.
  • Otherwise, it could be a hitherto undescribed variant of apocrine carcinoma.
  • This apocrine carcinoma on the forehead may have originated from either pluripotential cells or from apocrine glands at an unusual site.
  • [MeSH-major] Apocrine Glands / pathology. Carcinoma, Ductal / pathology. Forehead / pathology. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667178.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Keratin-19; 0 / Keratin-7; 0 / Mucin-1; 0 / PIP protein, human; EC 3.2.1.17 / Muramidase
  •  go-up   go-down


13. Fernandez-Flores A: Primary cutaneous apocrine carcinoma versus metastasis, a plea to the dermatopathology community. Am J Dermatopathol; 2010 Dec;32(8):853-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous apocrine carcinoma versus metastasis, a plea to the dermatopathology community.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / pathology. Neoplasms, Adnexal and Skin Appendage / pathology. Neoplasms, Second Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Dermatopathol. 2009 May;31(3):278-81 [19384070.001]
  • (PMID = 20431390.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


1
Advertisement
4. Bowling JC, Powles A, Nasiri N, Searle A, Bunker CB: Spontaneous regression of extramammary Paget's disease after excision of primary apocrine carcinoma, in an immunosuppressed patient. Br J Dermatol; 2005 Sep;153(3):676-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous regression of extramammary Paget's disease after excision of primary apocrine carcinoma, in an immunosuppressed patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16120170.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] England
  • [Number-of-references] 4
  •  go-up   go-down


15. Zelger BG, Stelzmueller I, Dunst KM, Zelger B: Solid apocrine carcinoma of the skin: report of a rare adnexal neoplasm mimicking lobular breast carcinoma. J Cutan Pathol; 2008 Mar;35(3):332-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid apocrine carcinoma of the skin: report of a rare adnexal neoplasm mimicking lobular breast carcinoma.
  • The so called 'sweat gland carcinoma' is a rare skin malignancy.
  • The differentiation between apocrine and eccrine neoplasms remains difficult.
  • A 71-year-old man presented with a morphea-like plaque of the right axilla which in punch biopsy was first suspected as metastasis of primary lobular breast carcinoma.
  • After further clinical and laboratory work up including immunohistochemistry the original diagnosis of a breast cancer had to be changed to solid apocrine carcinoma of the skin.
  • Solid apocrine carcinoma of the skin is a rare variant with apocrine differentiation.
  • A survey of the stereotypical presentation of this lesion and a comparison with lobular breast carcinoma and other types of apocrine carcinoma of the skin is given.
  • [MeSH-major] Adenocarcinoma / diagnosis. Apocrine Glands / pathology. Breast Neoplasms, Male / diagnosis. Carcinoma, Lobular / diagnosis. Sweat Gland Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251751.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Miyamoto T, Adachi K, Fujishima M: Axillary apocrine carcinoma with Paget's disease and apocrine naevus. Clin Exp Dermatol; 2009 Jul;34(5):e110-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axillary apocrine carcinoma with Paget's disease and apocrine naevus.
  • Apocrine carcinoma is a rare malignant sweat-gland neoplasm with apocrine differentiation.
  • There have been some reported cases of apocrine carcinoma with apocrine naevus.
  • The resected specimen showed apocrine adenocarcinoma with extramammary Paget's disease and apocrine naevus.
  • On resection of this enlarging right axilla, an apocrine naevus was found.
  • [MeSH-major] Adenocarcinoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Nevus / diagnosis. Paget Disease, Extramammary / diagnosis. Skin Neoplasms / diagnosis. Sweat Gland Neoplasms / diagnosis
  • [MeSH-minor] Aged. Apocrine Glands. Axilla. Humans. Male. Positron-Emission Tomography. Precancerous Conditions / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438526.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Bujas T, Pavić I, Lenicek T, Mijić A, Kruslin B, Tomas D: Axillary apocrine carcinoma associated with apocrine adenoma and apocrine gland hyperplasia. Acta Dermatovenerol Croat; 2007;15(3):148-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axillary apocrine carcinoma associated with apocrine adenoma and apocrine gland hyperplasia.
  • Apocrine carcinomas represent a rare group of tumors with a potential for destructive local invasion, regional and distant metastases, and are equally common in both sexes.
  • A case of a 79-year-old woman with axillary apocrine carcinoma associated with apocrine adenoma and apocrine gland hyperplasia is presented.
  • The cells contained abundant eosinophilic, finely granular cytoplasm with pleomorphic nuclei and showed apocrine-like decapitation.
  • In one area, the tumor was lobular and composed of tubular structures lined with one layer of uniform cuboidal or columnar eosinophilic cells, indicating a pre-existing apocrine adenoma.
  • Beneath the tumor, in the deep dermis and subcutaneous tissue, hyperplastic apocrine glands were also found.
  • This and previously reported cases suggest that apocrine hyperplasia and apocrine adenoma may represent successive steps in the development of apocrine carcinoma.
  • [MeSH-major] Adenoma, Sweat Gland / pathology. Apocrine Glands / pathology. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868540.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


18. Fernandez-Flores A: Mammaglobin immunostaining in the differential diagnosis between cutaneous apocrine carcinoma and cutaneous metastasis from breast carcinoma. Cesk Patol; 2009 Oct;45(4):108-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammaglobin immunostaining in the differential diagnosis between cutaneous apocrine carcinoma and cutaneous metastasis from breast carcinoma.
  • The differential diagnosis between cutaneous apocrine carcinoma (CAC) and cutaneous metastases from breast carcinoma is commonly difficult.
  • We used the antibody mammaglobin in order to study 10 cases of cutaneous metastasis of ductal breast carcinoma, and 2 cases of CAC.
  • Four cases of metastatic breast carcinoma also showed scattered positive cells.
  • One case of metastatic breast carcinoma did not show any expression of mammaglobin at all.
  • [MeSH-major] Apocrine Glands. Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Neoplasm Proteins / analysis. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary. Sweat Gland Neoplasms / diagnosis. Sweat Gland Neoplasms / secondary. Uteroglobin / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20301838.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


19. de la Torre Fernández de Vega J, Huguet P, Santana A, de Miguel CR, Rojo F, Ramón y Cajal S, Salido E: Apocrine carcinoma of the anogenital region. A case report including immunohistochemical and molecular study, discussion of differential diagnosis and a review of the literature. Int J Colorectal Dis; 2008 Jan;23(1):121-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine carcinoma of the anogenital region. A case report including immunohistochemical and molecular study, discussion of differential diagnosis and a review of the literature.
  • [MeSH-major] Apocrine Glands / pathology. Carcinoma / pathology. Gene Expression Regulation, Neoplastic. Immunohistochemistry. Perineum / pathology. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17333218.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] Germany
  • [Number-of-references] 0
  •  go-up   go-down


20. Tanese K, Wakabayashi A, Suzuki T, Miyakawa S: Immunoexpression of human epidermal growth factor receptor-2 in apocrine carcinoma arising in naevus sebaceous, case report. J Eur Acad Dermatol Venereol; 2010 Mar;24(3):360-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoexpression of human epidermal growth factor receptor-2 in apocrine carcinoma arising in naevus sebaceous, case report.
  • [MeSH-major] Carcinoma / immunology. Neoplasms, Multiple Primary / immunology. Nevus, Sebaceous of Jadassohn / immunology. Receptor, ErbB-2 / biosynthesis. Skin Neoplasms / immunology. Sweat Gland Neoplasms / immunology
  • [MeSH-minor] Aged. Apocrine Glands. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / immunology. Biopsy. Humans. Immunohistochemistry. Male

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19703100.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


21. Honma N, Saji S, Kurabayashi R, Aida J, Arai T, Horii R, Akiyama F, Iwase T, Harada N, Younes M, Toi M, Takubo K, Sakamoto G: Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in apocrine carcinoma of the breast. APMIS; 2008 Oct;116(10):923-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in apocrine carcinoma of the breast.
  • Apocrine carcinoma of the breast, which frequently expresses oestrogen receptor-beta (ER-beta) in the absence of ER-alpha and only infrequently is treated endocrinologically, gives an opportunity to investigate the clinicopathological role of ER-beta in breast cancer independent of ER-alpha expression or tamoxifen treatment.
  • Here we aimed to clarify the clinicopathological importance of ER-beta1 and ER-betacx (ER-beta2) in apocrine carcinomas, immunohistochemically examining expressions of ER-beta1 and ER-betacx in 47 apocrine carcinomas.
  • ER-beta1 positivity was also associated with favorable clinical outcome in 24 so-called triple-negative (ER-alpha-negative/PR-negative/HER2-negative) apocrine carcinomas.
  • ER-beta1 itself, independent of ER-alpha expression and tamoxifen treatment, seems to have a tumor-suppressive effect, at least in apocrine carcinomas.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Breast Neoplasms / mortality. Carcinoma, Ductal, Breast / mortality. Estrogen Receptor beta / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19132986.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor beta; 0 / Protein Isoforms
  •  go-up   go-down


22. Rütten A, Kutzner H, Mentzel T, Hantschke M, Eckert F, Angulo J, Rodríguez Peralto JL, Requena L: Primary cutaneous cribriform apocrine carcinoma: a clinicopathologic and immunohistochemical study of 26 cases of an under-recognized cutaneous adnexal neoplasm. J Am Acad Dermatol; 2009 Oct;61(4):644-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous cribriform apocrine carcinoma: a clinicopathologic and immunohistochemical study of 26 cases of an under-recognized cutaneous adnexal neoplasm.
  • BACKGROUND: Cribriform carcinoma is the histopathologic variant of cutaneous apocrine carcinoma characterized by interconnected solid aggregations of neoplastic cells that are punctuated by small round spaces.
  • METHODS: Twenty-six cases of primary cutaneous cribriform apocrine carcinoma were clinically, histopathologically, and immunohistochemically studied.
  • CONCLUSIONS: Primary cutaneous cribriform apocrine carcinoma is a distinctive but little-known variant of cutaneous apocrine carcinoma.
  • [MeSH-minor] Adult. Aged. Apocrine Glands / pathology. Biopsy. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Cytoplasm / pathology. Cytoplasm / ultrastructure. Diagnosis, Differential. Epithelial Cells / pathology. Epithelial Cells / ultrastructure. Female. Humans. Immunohistochemistry. Male. Microscopy, Electron. Microvilli / pathology. Microvilli / ultrastructure. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2011 Mar;64(3):599-601 [21315957.001]
  • (PMID = 19751882.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


23. Cham PM, Niehans GA, Foman N, Suwattee P: Primary cutaneous apocrine carcinoma presenting as carcinoma erysipeloides. Br J Dermatol; 2008 Jan;158(1):194-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous apocrine carcinoma presenting as carcinoma erysipeloides.
  • [MeSH-major] Apocrine Glands. Head and Neck Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986301.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


24. Honma N, Takubo K, Arai T, Younes M, Kasumi F, Akiyama F, Sakamoto G: Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast. APMIS; 2006 Oct;114(10):712-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast.
  • Gross cystic disease fluid protein-15 (GCDFP-15) is a commonly used apocrine marker; however, its expression was recently found to decrease in infiltrating, larger, or metastasizing apocrine carcinomas of the breast.
  • In the breast, monoclonal antibody (MAb) B72.3 has been reported to be useful as an apocrine marker although it is used for that purpose much less frequently than GCDFP-15.
  • In the search for a more consistent apocrine marker, immunoreactivity for MAb B72.3 was examined in apocrine carcinomas at different stages and compared with GCDFP-15.
  • 47 of 51 apocrine carcinomas (92%) and 9 of 62 ordinary carcinomas (15%) were MAb B72.3 positive, while 39 of 51 apocrine carcinomas (76%) and 13 of 62 ordinary carcinomas (21%) were GCDFP-15 positive.
  • The combined usage of MAb B72.3 with GCDFP-15 was useful to confirm the diagnosis of apocrine carcinoma, especially for advanced tumors, with only two cases being negative for both MAb B72.3 and GCDFP-15.
  • Whether these two cases should be differentiated from ordinary apocrine carcinomas remains to be investigated.
  • [MeSH-major] Apocrine Glands / pathology. Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Breast Neoplasms / secondary. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / secondary. Carrier Proteins / metabolism. Glycoproteins / metabolism. Immunohistochemistry / methods. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004974.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / PIP protein, human
  •  go-up   go-down


25. Akhtar I, Ispas CL, Flowers R, Siddiqi A, Young L, Donnellan KA, Heard K, Baliga M: Ductopapillary apocrine carcinoma of the eyelid metastatic to the parotid gland: report of a case diagnosed by fine-needle aspiration biopsy. Diagn Cytopathol; 2009 Feb;37(2):91-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductopapillary apocrine carcinoma of the eyelid metastatic to the parotid gland: report of a case diagnosed by fine-needle aspiration biopsy.
  • Ductopapillary apocrine carcinoma (DPAC) of the eyelid is a rare malignant neoplasm in the periocular region.
  • We report a case of a 65-year-old African-American male with a history of ductopapillary apocrine adenocarcinoma of the eyelid, diagnosed 6 weeks ago now presenting with a recurrence in the same area.
  • FNAB of the parotid mass showed a well-differentiated papillary adenocarcinoma with a cystic component, similar to a previously excised ductopapillary apocrine adenocarcinoma of the eyelid.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Eyelid Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Parotid Neoplasms / diagnosis. Sweat Gland Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19021198.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Glycoproteins; 0 / PIP protein, human
  •  go-up   go-down


26. Gercovich N, Gil Deza E, Russo M, Garcia Gerardi C, Diaz C, Morgenfeld E, Rolnik B, Emina J, Rivarola E, Gercovich FG: Early-stage male breast cancer: A 10-year experience. J Clin Oncol; 2009 May 20;27(15_suppl):e11630

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumoral type= Invasive Ductal Carcinoma 12 pt.
  • Tumoral subtype= NOS 9 pt (75%) Apocrine 2 pt (17%) Micropapillar 1 pt (8%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961181.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Treiyer A, Haben B, Röttger P, Steffens J: First male apocrine genital carcinoma mimicking a penile cancer. Urology; 2008 Mar;71(3):546.e11-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First male apocrine genital carcinoma mimicking a penile cancer.
  • Perineal apocrine carcinoma is a rare malignant tumor that has its origin in the apocrine sudoriparous glands of the genital and perianal regions.
  • We report a case of a genital apocrine carcinoma located at the penile basis.
  • To our knowledge our report represents the first case of a pathologically confirmed genital apocrine carcinoma mimicking a penile cancer.
  • [MeSH-major] Apocrine Glands. Penile Neoplasms / diagnosis. Sweat Gland Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342207.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Shimato S, Wakabayashi T, Mizuno M, Nakahara N, Hatano H, Natsume A, Ishii D, Hasegawa Y, Hyodo I, Nagasaka T, Yoshida J: Brain metastases from apocrine carcinoma of the scalp: case report. J Neurooncol; 2006 May;77(3):285-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases from apocrine carcinoma of the scalp: case report.
  • Apocrine carcinoma is an extremely rare malignant neoplasm that occurs most frequently in the axilla.
  • However, a literature search did not reveal any report describing the detailed clinical course of brain metastases from apocrine carcinoma.
  • We report a case of a 54-year-old male who suffered from multiple brain metastases from apocrine carcinoma that had originated in the scalp 6 years before.
  • To our knowledge this is the first reported case of metastatic brain tumor from apocrine carcinoma.
  • [MeSH-major] Apocrine Glands / pathology. Brain Neoplasms / secondary. Carcinoma / secondary. Lung Neoplasms / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314948.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


29. Honma N, Takubo K, Akiyama F, Kasumi F, Sawabe M, Arai T, Hosoi T, Yoshimura N, Harada N, Younes M, Sakamoto G: Expression of oestrogen receptor-beta in apocrine carcinomas of the breast. Histopathology; 2007 Mar;50(4):425-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of oestrogen receptor-beta in apocrine carcinomas of the breast.
  • AIMS: Apocrine carcinoma of the breast seldom expresses oestrogen receptors (ER) or progesterone receptors (PR), but frequently expresses androgen receptors (AR).
  • Because of this unusual hormone receptor status, it has been suggested that oestrogens have a less important role in the pathogenesis of apocrine carcinoma.
  • The ER status of apocrine carcinoma has been studied for one kind of ER, the classic receptor now named ER-alpha; however, the status of ER-beta, a secondary oestrogen receptor, has not been examined systematically in apocrine carcinoma.
  • The aim was to study ER-beta status in apocrine carcinoma.
  • METHODS AND RESULTS: The expression of ER-beta was examined immunohistochemically in 48 apocrine carcinomas and compared with clinicopathological factors and ER-alpha, PR and AR status.
  • CONCLUSIONS: The significance of oestrogens in apocrine carcinoma should not be dismissed at present when the role of ER-beta remains to be determined.
  • Studying the action of oestrogen or antioestrogen in apocrine carcinoma may reveal a role for ER-beta independent of ER-alpha and raise the potential of hormonal therapy for these tumours.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal / metabolism. Carcinoma, Ductal / secondary. Estrogen Receptor alpha / biosynthesis. Female. Humans. Immunohistochemistry. In Situ Hybridization. Middle Aged. RNA, Messenger / biosynthesis. Receptor, ErbB-2 / metabolism. Receptors, Androgen / biosynthesis. Receptors, Progesterone / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448017.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / RNA, Messenger; 0 / Receptors, Androgen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


30. Bagwan IN, Taylor A, Dina R: Metastatic apocrine carcinoma of female genital tract. J Clin Pathol; 2009 Mar;62(3):287-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic apocrine carcinoma of female genital tract.
  • [MeSH-minor] Aged. Apocrine Glands / pathology. Female. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251959.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


31. Gallerani E, Ciriolo M, Rossini C, Cavalli F: Axillary apocrine carcinoma with brain metastases. J Clin Oncol; 2007 Dec 10;25(35):5655-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axillary apocrine carcinoma with brain metastases.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma / secondary. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apocrine Glands. Axilla. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neck. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18065737.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Weinreb I, Bergfeld WF, Patel RM, Ghazarian DM: Apocrine carcinoma in situ of sweat duct origin. Am J Surg Pathol; 2009 Jan;33(1):155-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine carcinoma in situ of sweat duct origin.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Skin Appendage / pathology. Scalp / pathology. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Surg Pathol. 2008 May;32(5):682-90 [18347508.001]
  • (PMID = 18971780.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Misago N, Aoki S, Shinoda Y, Toda S, Narisawa Y: Cartilaginous matrix-producing apocrine carcinoma of the skin. Br J Dermatol; 2010 Jul;163(1):215-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cartilaginous matrix-producing apocrine carcinoma of the skin.
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20331446.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


34. Khalbuss WE: Cytomorphology of rare malignant tumors of the breast. Clin Lab Med; 2005 Dec;25(4):761-75, vii
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article reviews cytomorphology of rare malignant tumors of the breast: squamous carcinoma, metaplastic carcinoma, adenoid cystic carcinoma, apocrine carcinoma, secretory carcinoma, lipid-rich carcinoma, and carcinoma with choriocarcinomatous features.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308090.001).
  • [ISSN] 0272-2712
  • [Journal-full-title] Clinics in laboratory medicine
  • [ISO-abbreviation] Clin. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 80
  •  go-up   go-down


35. Miyamoto T, Inoue S, Adachi K, Takada R: Differential expression of mucin core proteins and keratins in apocrine carcinoma, extramammary Paget's disease and apocrine nevus. J Cutan Pathol; 2009 May;36(5):529-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of mucin core proteins and keratins in apocrine carcinoma, extramammary Paget's disease and apocrine nevus.
  • BACKGROUND: Apocrine carcinomas are rare, the immunohistochemical characterizations that are incomplete.
  • The purpose of this study was to determine the immunohistochemical characteristics of mucin core proteins and keratins in apocrine carcinoma, extramammary Paget's disease (EMPD) and apocrine nevus.
  • METHODS: We report four cases of apocrine carcinomas along with immunohistochemical analyses: (i) an axillary apocrine carcinoma with an apocrine nevus, (ii) an inguinal apocrine carcinoma, (iii) a vulvar apocrine carcinoma with EMPD and (iv) an axillary apocrine carcinoma with EMPD and an apocrine nevus.
  • RESULTS: The tumor cells of apocrine carcinomas, EMPD and apocrine nevi displayed a positive reaction to MUC-1 and CK7 and a negative reaction to CK20.
  • Apocrine carcinomas had high molecular weight (HMW) cytokeratin(+)/CK5(+)/CK14(-)/MUC5AC(-), EMPD with underlying apocrine carcinoma had HMW cytokeratin(-)/CK5(-)/CK14(-)/MUCA5AC(-) and the apocrine nevi had HMW cytokeratin(+)/CK5(+)/CK14(+)/MUCA5AC(+).
  • CONCLUSION: The immunohistochemical findings suggest that apocrine carcinomas, apocrine nevi and EMPD with underlying apocrine carcinomas are quite different, even though they are all derived from apocrine glands.
  • [MeSH-major] Carcinoma, Skin Appendage / metabolism. Keratins / biosynthesis. Mucins / biosynthesis. Nevus / metabolism. Paget Disease, Extramammary / metabolism. Sweat Gland Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apocrine Glands / metabolism. Apocrine Glands / pathology. Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. Male

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19476520.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins; 68238-35-7 / Keratins
  •  go-up   go-down


36. Hernandez JM, Copeland EM 3rd: Infiltrating apocrine adenocarcinoma with extramammary pagetoid spread. Am Surg; 2007 Mar;73(3):307-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infiltrating apocrine adenocarcinoma with extramammary pagetoid spread.
  • Apocrine adenocarcinoma is a rare malignancy with invasive potential.
  • We report on a case of apocrine carcinoma presenting with lymph node infiltration and extensive extramammary Paget's disease.
  • [MeSH-major] Adenocarcinoma / pathology. Apocrine Glands. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17375797.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Maury G, Guillot B, Bessis D, Cribier B, Girard C: [Unusual axillary apocrine carcinoma of the skin: histological diagnostic difficulties]. Ann Dermatol Venereol; 2010 Aug-Sep;137(8-9):555-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual axillary apocrine carcinoma of the skin: histological diagnostic difficulties].
  • [Transliterated title] Carcinome apocrine cutané axillaire inhabituel : difficultés diagnostiques histologiques.
  • BACKGROUND: Apocrine carcinoma of the skin (ACS) is a rare adnexal neoplasm presenting as an indurated slow-growing dermal or subcutaneous plaque that often occurs in the axilla.
  • Histological distinction between ACS and cutaneous metastases of breast carcinoma may be difficult.
  • The pattern of the tumour and immunohistochemical staining suggested a diagnosis of breast carcinoma metastasis.
  • The differential diagnostic between axillary ACS and metastasis of lobular breast carcinoma has been discussed recently.
  • CONCLUSION: We report a new case of axillary ACS histologically mimicking lobular breast carcinoma metastasis.
  • [MeSH-major] Carcinoma / diagnosis. Sweat Gland Neoplasms / diagnosis
  • [MeSH-minor] Axilla. Breast Neoplasms, Male / diagnosis. Carcinoma, Lobular / secondary. Diagnosis, Differential. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20804902.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  •  go-up   go-down


38. Pai RR, Kini JR, Achar C, Rau A, Kini H: Apocrine (cutaneous) sweat gland carcinoma of axilla with signet ring cells: a diagnostic dilemma on fine-needle aspiration cytology. Diagn Cytopathol; 2008 Oct;36(10):739-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine (cutaneous) sweat gland carcinoma of axilla with signet ring cells: a diagnostic dilemma on fine-needle aspiration cytology.
  • Carcinoma arising in the apocrine sweat glands is rare and there are few reports describing the cytological features of this neoplasm.
  • We describe the cytological features of a histologically confirmed apocrine carcinoma occurring in a 55-year-old man who presented with an ulcerated mass in the right axilla.
  • In an axillary mass lesion, cytological features along with clinical correlation are essential to distinguish primary apocrine carcinoma from mammary neoplasms with signet ring cells and other metastatic adenocarcinomas.
  • [MeSH-major] Axilla. Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / pathology. Sweat Gland Neoplasms / diagnosis. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773442.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Tanaka K, Imoto S, Wada N, Sakemura N, Hasebe K: Invasive apocrine carcinoma of the breast: clinicopathologic features of 57 patients. Breast J; 2008 Mar-Apr;14(2):164-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive apocrine carcinoma of the breast: clinicopathologic features of 57 patients.
  • Apocrine carcinoma is a rare, unique, and morphologically distinctive type of invasive ductal carcinoma (IDC).
  • The features of invasive apocrine carcinoma (IAC) and their possible prognostic implications have not been fully investigated.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology
  • [MeSH-minor] Aged. Apocrine Glands / pathology. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Middle Aged. Receptors, Estrogen. Receptors, Progesterone. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248561.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


40. Kazakov DV, Bisceglia M, Calonje E, Hantschke M, Kutzner H, Mentzel T, Michal M, Mukensnabl P, Spagnolo DV, Rütten A, Rose C, Urso C, Vazmitel M, Zelger B: Tubular adenoma and syringocystadenoma papilliferum: a reappraisal of their relationship. An interobserver study of a series, by a panel of dermatopathologists. Am J Dermatopathol; 2007 Jun;29(3):256-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TA has been recently suggested to represent a carcinoma.
  • Four observers blindly assessed 67 cases of TA, SCAP, and their lookalikes (poroma, apocrine adenoma, apocrine carcinoma; all lesions focally featuring a pseudopapillary pattern), and classified the lesions into one of four categories:.
  • All observers agreed that the lesions were benign; the only apocrine carcinoma included was recognized as such by all observers.
  • [MeSH-major] Adenoma, Sweat Gland / diagnosis. Cystadenoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Sweat Gland Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Syringocystadenoma papilliferum.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519623.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


41. Celis JE, Moreira JM, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans V, Rank F: Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. Mol Oncol; 2007 Jun;1(1):97-119
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.
  • The strategy we have been pursuing to identify early apocrine breast lesions is based on the postulate that invasive apocrine carcinomas evolve from epithelial cells in terminal duct lobular units (TDLUs) in a stepwise manner that involves apocrine metaplasia of normal breast epithelia, hyperplasia, atypia, and apocrine carcinoma in situ.
  • First, we identify specific protein biomarkers for benign apocrine metaplasia and thereafter we search for biomarkers that are highly overexpressed by pure invasive apocrine carcinomas.
  • Here we present studies in which we have used antibodies against components of a benign apocrine signature that includes 15-prostaglandin dehydrogenase (15-PGDH), a protein that is expressed by all benign apocrine lesions, and markers that are highly overexpressed by pure invasive apocrine carcinomas such as MRP14 (S100A9), psoriasin (S100A7), and p53 to identify precancerous lesions in sclerosing adenosis (SA) with apocrine metaplasia.
  • SA with apocrine metaplasia, i.e. apocrine adenosis (AA), presents with a higher degree of atypical apocrine hyperplasia, and these lesions are believed to be precursors of apocrine carcinoma, in situ and invasive.
  • Analysis of 24 selected SA samples with apocrine metaplasia revealed non-obligate putative apocrine precancerous lesions that displayed some, or in same cases all the three markers associated with pure invasive apocrine carcinomas.
  • These studies also revealed p53 positive, non-apocrine putative precancerous lesions as well as novel phenotypes for ME and some luminal cells characterized by the expression of cytokeratin 15.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):39-50 [11801722.001]
  • [Cites] Mod Pathol. 1994 Oct;7(8):813-8 [7838835.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):785-93; discussion 793 [12454517.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jul;104(1):75-85 [17009105.001]
  • [Cites] J Cell Biol. 1997 Dec 29;139(7):1873-84 [9412479.001]
  • [Cites] Adv Anat Pathol. 2004 Jan;11(1):1-9 [14676636.001]
  • [Cites] Eur J Radiol. 2005 Apr;54(1):6-14 [15797289.001]
  • [Cites] Am J Pathol. 1983 Feb;110(2):105-12 [6130702.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):146-9 [7819031.001]
  • [Cites] Radiographics. 1999 Oct;19 Spec No:S80-3 [10517446.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):459-72 [17157787.001]
  • [Cites] Am J Surg. 1990 May;159(5):473-8 [2334010.001]
  • [Cites] J Pathol. 2004 Mar;202(3):274-85 [14991892.001]
  • [Cites] Virchows Arch. 1998 Mar;432(3):255-60 [9532005.001]
  • [Cites] Am J Surg. 1993 Sep;166(3):237-43 [8368433.001]
  • [Cites] J Cutan Pathol. 1999 Mar;26(3):113-8 [10235375.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1316-23 [16835330.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):555-69 [15644556.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):26-41 [19383285.001]
  • [Cites] Anticancer Res. 1988 Nov-Dec;8(6):1217-22 [3064712.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):693-7 [10505026.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):13-8 [10658905.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):872-9 [11978511.001]
  • [Cites] Biochem Pharmacol. 2006 Nov 30;72(11):1622-31 [16846592.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Lab Invest. 2002 Jun;82(6):737-46 [12065684.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):323-9 [10880402.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):355-61 [10197443.001]
  • [Cites] Ir J Med Sci. 1989 Jun;158(6):137-40 [2570047.001]
  • [Cites] Recent Results Cancer Res. 1998;152:11-21 [9928543.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Trends Cell Biol. 1996 Sep;6(9):341-7 [15157431.001]
  • [Cites] J Cell Biol. 2007 Apr 9;177(1):87-101 [17420292.001]
  • [Cites] Breast Cancer Res. 2003;5(5):R151-6 [12927046.001]
  • [Cites] BMJ. 1997 Mar 29;314(7085):925-8 [9099114.001]
  • [Cites] J Dermatol Sci. 2007 Feb;45(2):147-50 [17071058.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]
  • [Cites] Virchows Arch. 2006 May;448(5):525-31 [16570182.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2805-9 [7872722.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):8-16 [12794751.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):261-72 [16807805.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1340-2 [11684218.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):470-9 [9469330.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7818-23 [16885386.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Med Princ Pract. 2007;16(1):1-14 [17159357.001]
  • [Cites] Subcell Biochem. 1998;31:205-62 [9932494.001]
  • [Cites] J Invest Dermatol. 1991 Oct;97(4):701-12 [1940442.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4782-90 [8840999.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):1033-67 [17158753.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2935-44 [16631754.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2529-37 [8640702.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1473-81 [16273201.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] FEBS J. 2005 Jan;272(1):2-15 [15634327.001]
  • [Cites] Ann N Y Acad Sci. 1990;586:49-52 [2141459.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2006 Oct;81(1-2):14-30 [16997128.001]
  • [Cites] Mol Cell Proteomics. 2006 Mar;5(3):462-83 [16316978.001]
  • [Cites] Adv Anat Pathol. 2002 May;9(3):185-97 [11981114.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):344-9 [16400324.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):349-54 [10197442.001]
  • [Cites] J Clin Pathol. 1995 Aug;48(8):737-42 [7560201.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):369-72 [7927943.001]
  • [Cites] Pathol Res Pract. 1997;193(11-12):753-8 [9521507.001]
  • [Cites] Eur J Gynaecol Oncol. 1992;13(4):309-15 [1325346.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):734-46 [15897740.001]
  • [Cites] Adv Anat Pathol. 2003 May;10(3):113-24 [12717115.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):207-14 [11141494.001]
  • [Cites] JAMA. 1995 Jan 11;273(2):149-54 [7799496.001]
  • [Cites] Breast Cancer Res. 2005;7(5):190-7 [16168137.001]
  • [Cites] Mol Cell Proteomics. 2003 Jun;2(6):369-77 [12832461.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1307-12 [17182657.001]
  • [Cites] Methods. 2003 Jul;30(3):247-55 [12798139.001]
  • [Cites] Am J Clin Pathol. 2000 May;113(5 Suppl 1):S3-18 [11993707.001]
  • [Cites] Nat Chem Biol. 2006 Dec;2(12):689-700 [17108987.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):675-81 [15220356.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):231-47 [16807803.001]
  • [Cites] Dev Biol. 1999 Feb 1;206(1):88-99 [9918697.001]
  • [Cites] Histopathology. 2001 Mar;38(3):221-4 [11260302.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):97-119 [19383289.001]
  • [Cites] Breast Cancer Res Treat. 2001 May;67(2):93-109 [11519870.001]
  • [Cites] Breast. 2002 Dec;11(6):466-72 [14965711.001]
  • [Cites] J Pathol. 2002 Mar;196(3):287-91 [11857491.001]
  • [Cites] J Mol Biol. 1993 Jun 20;231(4):982-98 [8515476.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6):642-6 [17145342.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Int J Cancer. 2000 Jun 15;86(6):835-41 [10842198.001]
  • [Cites] Med Mol Morphol. 2006 Mar;39(1):8-13 [16575508.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):638-42 [17136094.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1051-61 [15254552.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):749-51 [10797302.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):381-6 [3557440.001]
  • [Cites] J Biol Chem. 1975 May 25;250(10):4007-21 [236308.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):449-55 [12447674.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1076-91 [15252316.001]
  • [Cites] Differentiation. 1998 Aug;63(4):201-13 [9745711.001]
  • [Cites] Endocr Relat Cancer. 2001 Mar;8(1):47-61 [11350726.001]
  • [Cites] Mod Pathol. 1991 Jan;4(1):1-5 [2020652.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):387-94 [17079091.001]
  • [Cites] Histopathology. 2001 Oct;39(4):433-4 [11683946.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2328-38 [16314837.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11326-34 [16357139.001]
  • [Cites] Eur J Cancer. 2004 May;40(8):1179-87 [15110881.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jan;10(1):61-74 [15886887.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):492-522 [15695426.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):43-7 [11782356.001]
  • [Cites] Am J Surg Pathol. 1991 Jul;15(7):687-94 [2058763.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):327-44 [14754989.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):3003-9 [10383167.001]
  • [Cites] Pathology. 2006 Feb;38(1):16-20 [16484002.001]
  • [Cites] Hum Pathol. 1994 Apr;25(4):337-42 [8163266.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] J Endocrinol. 1992 Mar;132(3):R5-8 [1564416.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):84-96 [18516279.001]
  • [Cites] Cancer Detect Prev. 2001;25(3):262-7 [11425268.001]
  • (PMID = 19383289.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


42. Shim HS, Jung WH, Kim H, Park K, Cho NH: Expression of androgen receptors and inhibin/activin alpha and betaA subunits in breast apocrine lesions. APMIS; 2006 May;114(5):352-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of androgen receptors and inhibin/activin alpha and betaA subunits in breast apocrine lesions.
  • We investigated the role of these hormones in breast apocrine lesions (BAL) using immunohistochemistry to study androgen receptors (AR) and the inhibin/activin alpha and betaA subunits.
  • Forty-two cases of BAL were evaluated, including 22 cases of fibrocystic disease (FCD) showing prominent apocrine changes, 10 intraductal papillomas with extensive apocrine metaplasia, 5 cases of apocrine carcinoma in situ (CIS), and 5 cases of apocrine carcinoma.
  • Fifty non-apocrine lesions were included as controls: 20 cases of FCD, 5 cases of DCIS, and 25 cases of invasive ductal carcinoma.
  • AR was more frequently expressed in BAL than in non-apocrine lesions (p=0.001).
  • As the expression of the alpha and betaA subunits reflects inhibin and activin A, respectively, AR and activin A may be implicated in apocrine morphogenesis, but not in tumor progression.
  • [MeSH-major] Apocrine Glands / metabolism. Breast Neoplasms / metabolism. Carcinoma in Situ / metabolism. Fibrocystic Breast Disease / metabolism. Inhibin-beta Subunits / metabolism. Inhibins / metabolism. Metaplasia / metabolism. Papilloma, Intraductal / metabolism. Receptors, Androgen / metabolism. Sweat Gland Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16725011.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Receptors, Androgen; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; 93443-12-0 / Inhibin-beta Subunits
  •  go-up   go-down


43. Honma N, Takubo K, Akiyama F, Sawabe M, Arai T, Younes M, Kasumi F, Sakamoto G: Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Histopathology; 2005 Aug;47(2):195-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
  • AIMS: Apocrine carcinoma of the breast is typically, though not always, positive for gross cystic disease fluid protein-15 (GCDFP-15).
  • In order to clarify the clinical significance of GCDFP-15 in apocrine carcinomas, GCDFP-15 expression was examined in apocrine carcinomas of different stages and compared with clinicopathological factors.
  • Apocrine lesions reportedly exhibit an unusual immunohistochemical status, expressing androgen receptors (AR) instead of oestrogen receptors (ER), progesterone receptors (PR), or bcl-2.
  • METHODS AND RESULTS: Fifty-two apocrine carcinomas were examined immunohistochemically.
  • CONCLUSIONS: GCDFP-15 positivity is transient and should not be considered a definitive marker of apocrine carcinomas.
  • Cases which have apocrine features but lack GCDFP-15 expression should rather be considered as advanced apocrine carcinomas.
  • ER/PR/bcl-2 negativity will sometimes be helpful to confirm the diagnosis of apocrine carcinoma, because it is more consistent than GCDFP-15/AR positivity.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / pathology. Carrier Proteins / biosynthesis. Glycoproteins / biosynthesis. Receptors, Androgen / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Proto-Oncogene Proteins c-bcl-2 / analysis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045781.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Glycoproteins; 0 / PIP protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Androgen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


44. Filipovski V, Banev S, Janevska V, Dukova B: Granular cell tumor of the breast: a case report and review of literature. Cases J; 2009;2:8551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main histological feature is granular cytoplasm of the tumor cells.From a clinical point of view there is a similarity between granular cell tumor and mammary carcinoma on mammography and ultrasound.
  • Pathohistologically, sometimes, differential diagnostic difficulties exist concerning apocrine carcinoma, histiocytic lesions and metastatic neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1992 Feb;116(2):206-8 [1733419.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1984;403(4):391-400 [6330972.001]
  • [Cites] Eur J Radiol. 1994 Nov;19(1):56-9 [7859762.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):709-11 [10782152.001]
  • [Cites] Cancer. 1953 Jul;6(4):786-9 [13059774.001]
  • [Cites] Obstet Gynecol. 1989 May;73(5 Pt 2):898-900 [2539575.001]
  • [Cites] Am J Clin Pathol. 1949 Jun;19(6):522-35 [18150636.001]
  • [Cites] J Surg Oncol. 1980;13(4):301-16 [6246310.001]
  • [Cites] South Med J. 1995 Nov;88(11):1146-8 [7481988.001]
  • [Cites] Diagn Cytopathol. 1996 Dec;15(5):403-8 [8989543.001]
  • [Cites] South Med J. 1997 Nov;90(11):1149-51 [9386062.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(4):333-4 [12214737.001]
  • [Cites] AMA Arch Pathol. 1955 Dec;60(6):663-8 [13268207.001]
  • [Cites] Arch Pathol Lab Med. 1988 Mar;112(3):302-3 [2830865.001]
  • (PMID = 19918386.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2769456
  •  go-up   go-down


45. Celis JE, Gromova I, Gromov P, Moreira JM, Cabezón T, Friis E, Rank F: Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. FEBS Lett; 2006 May 22;580(12):2935-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia.
  • Breast cancer is a heterogeneous disease that encompasses a wide range of histopathological types including: invasive ductal carcinoma, lobular carcinoma, medullary carcinoma, mucinous carcinoma, tubular carcinoma, and apocrine carcinoma among others.
  • Pure apocrine carcinomas represent about 0.5% of all invasive breast cancers according to the Danish Breast Cancer Cooperative Group Registry, and despite the fact that they are morphologically distinct from other breast lesions, there are at present no standard molecular criteria available for their diagnosis.
  • In addition, the relationship between benign apocrine changes and breast carcinoma is unclear and has been a matter of discussion for many years.
  • Recent proteome expression profiling studies of breast apocrine macrocysts, normal breast tissue, and breast tumours have identified specific apocrine biomarkers [15-hydroxyprostaglandin dehydrogenase (15-PGDH) and hydroxymethylglutaryl coenzyme A reductase (HMG-CoA reductase)] present in early and advanced apocrine lesions.
  • These biomarkers in combination with proteins found to be characteristically upregulated in pure apocrine carcinomas (psoriasin, S100A9, and p53) provide a protein expression signature distinctive for benign apocrine metaplasias and apocrine cystic lesions.
  • These studies have also presented compelling evidence for a direct link, through the expression of the prostaglandin degrading enzyme 15-PGDH, between early apocrine lesions and pure apocrine carcinomas.
  • Moreover, specific antibodies against the components of the expression signature have identified precursor lesions in the linear histological progression to apocrine carcinoma.
  • Finally, the identification of proteins that characterize the early stages of mammary apocrine differentiation such as 15-PGDH, HMG-CoA reductase, and cyclooxygenase 2 (COX-2) has opened a window of opportunity for pharmacological intervention, not only in a therapeutic manner but also in a chemopreventive setting.
  • Here we review published and recent results in the context of the current state of research on breast apocrine cancer.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / pathology. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631754.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 85
  •  go-up   go-down


46. Watanabe K, Nomura M, Hashimoto Y, Hanzawa M, Hoshi T: Fine-needle aspiration cytology of apocrine adenosis of the breast: report on three cases. Diagn Cytopathol; 2007 May;35(5):296-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration cytology of apocrine adenosis of the breast: report on three cases.
  • Apocrine adenosis is a distinctive breast lesion, which can sometimes be misdiagnosed as malignant histologically.
  • We report fine-needle aspiration (FNA) cytology of three cases of apocrine adenosis.
  • Apocrine metaplasia with nuclear atypia mimicking apocrine carcinoma was prominent in one case, whereas one case lacked definite apocrine features.
  • Although FNA cytology of apocrine adenosis has the potential to be misinterpreted as malignant, the naked nuclei of background and less hyperchromatic nuclear features may be useful in distinguishing apocrine adenosis from carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17427223.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Kuroda N, Ohara M, Inoue K, Mizuno K, Fujishima N, Hamaguchi N, Lee GH: The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma. Med Mol Morphol; 2009 Jun;42(2):128-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma.
  • Recently, the concept of basal-like carcinoma has been proposed.
  • However, there are only a few reports about the relationship between triple-negative cancer and basal-like carcinoma.
  • Eight tumors (4 metaplastic carcinomas, 2 invasive ductal carcinomas, 1 invasive papillary carcinoma, and 1 medullary carcinoma) were positive for more than three markers among cytokeratins 5, 14, and 17, and p63.
  • Three tumors (2 invasive ductal carcinomas and 1 apocrine carcinoma) were completely negative for all markers.
  • Finally, we conclude that the majority of triple-negative cancer may correspond to basal-like carcinoma, but the two entities are not identical.
  • The use of combination immunohistochemistry including cytokeratins 5, 14, and 17 and p63 may contribute to the detection of basal-like carcinoma.
  • [MeSH-major] Breast Neoplasms / classification. Carcinoma, Basal Cell / classification

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Triple Negative Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Anat Pathol. 2007 Nov;14(6):419-30 [18049131.001]
  • [Cites] J Clin Pathol. 2005 Dec;58(12):1299-304 [16311351.001]
  • [Cites] Adv Anat Pathol. 2007 Sep;14(5):358-73 [17717437.001]
  • [Cites] Histopathology. 2008 Jan;52(1):82-90 [18171419.001]
  • [Cites] Histopathology. 2008 Jan;52(1):91-8 [18171420.001]
  • [Cites] Cancer Sci. 2005 Jan;96(1):48-53 [15649255.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] Med Mol Morphol. 2008 Jun;41(2):117-20 [18592167.001]
  • [Cites] Histopathology. 2008 Jan;52(1):67-81 [18171418.001]
  • [Cites] Histopathology. 2008 Jan;52(1):108-18 [18171422.001]
  • [Cites] Hum Pathol. 2006 Sep;37(9):1217-26 [16938528.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):347-53 [15725803.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4003-11 [15930334.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):5988-97 [15447982.001]
  • [Cites] Histopathology. 2005 Nov;47(5):458-66 [16241993.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5 [14519755.001]
  • [Cites] Histopathology. 2006 Jul;49(1):22-34 [16842243.001]
  • (PMID = 19536621.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CKAP4 protein, human; 0 / Estrogen Receptor alpha; 0 / Keratin-14; 0 / Keratin-5; 0 / Membrane Proteins; 0 / Receptors, Progesterone
  •  go-up   go-down


48. Kim ES, Lee DP, Lee MW, Choi JH, Moon KC, Koh JK: Cutaneous metastasis of uterine papillary serous carcinoma. Am J Dermatopathol; 2005 Oct;27(5):436-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous metastasis of uterine papillary serous carcinoma.
  • Uterine papillary serous carcinoma (UPSC) is an uncommon highly malignant variant of endometrial adenocarcinoma that histologically and clinically resembles papillary serous carcinoma of the ovary.
  • This case demonstrates a very rare case of cutaneous metastasis of uterine papillary serous carcinoma.
  • A 54-year-old Korean female developed multiple pruritic skin nodules on the pubic area 13 months later after diagnosis of uterine papillary serous carcinoma.
  • A biopsy of the skin lesions showed papillary serous carcinoma, compatible with her primary tumor.
  • Without clinical history, it is difficult to distinguish other types of metastatic carcinoma to the skin and primary apocrine carcinoma of the skin from metastatic uterine papillary serous carcinoma.
  • Whereas uterine papillary serous carcinoma only rarely involves the skin, this entity should be included in the differential diagnosis of papillary adenocarcinoma in the skin.
  • [MeSH-minor] Bone Neoplasms / secondary. Carcinoma, Transitional Cell / pathology. Female. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Middle Aged. Neoplasms, Second Primary. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16148416.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Ohri A, Jetly D, Shukla K, Bansal R: Cytological grading of breast neoplasia and its correlation with histological grading. Indian J Pathol Microbiol; 2006 Apr;49(2):208-13
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In our study we have analyzed 50 cases of breast carcinoma which included invasive ductal carcinoma, invasive lobular carcinoma, mucinous carcinoma, stromal sarcoma, apocrine carcinoma, papillary carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933716.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  •  go-up   go-down


50. Mahalingam M, Srivastava A, Hoang MP: Expression of stem-cell markers (cytokeratin 15 and nestin) in primary adnexal neoplasms-clues to etiopathogenesis. Am J Dermatopathol; 2010 Dec;32(8):774-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The overlap in histopathologic features and immunoprofile of eccrine and apocrine neoplasms confounds basic issues relating to lineage of these entities.
  • RESULTS: CK15 and nestin expression were noted in 39 of 78 (50%) and 36 of 78 (46%) cases in the benign group, respectively (8 cutaneous mixed tumor, 10 hidradenoma papilliferum, 9 apocrine cystadenoma, 11 cylindroma and/or spiradenoma, and 9 poroma/dermal duct tumor).
  • CK15 and nestin expression were noted in 11 of 23 (48%) and 7 of 23 (30%) cases in the malignant group, respectively (6 microcystic adnexal carcinoma, 7 porocarcinoma, and 9 eccrine carcinoma).
  • Except 1, both markers were negative in 4 syringocystadenoma papilliferum, 10 hidradenoma, 1 syringofibroadenoma, 10 syringoma, 1 eccrine adenoma, 8 poroma/dermal duct tumor, 5 eccrine hidrocystoma, and 1 apocrine carcinoma.
  • CONCLUSIONS: Given that follicular germinative cells give rise to the folliculosebaceous apocrine unit, expression of CK15 and nestin in the majority of cutaneous mixed tumor, hidradenoma papilliferum, apocrine cystadenoma, and cylindroma/spiradenoma is suggestive of an apocrine origin/differentiation of these neoplasms.
  • [MeSH-major] Apocrine Glands / chemistry. Biomarkers, Tumor / analysis. Eccrine Glands / chemistry. Intermediate Filament Proteins / analysis. Keratin-15 / analysis. Neoplasms, Adnexal and Skin Appendage / chemistry. Neoplastic Stem Cells / chemistry. Nerve Tissue Proteins / analysis. Sweat Gland Neoplasms / chemistry

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20700038.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / KRT15 protein, human; 0 / Keratin-15; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


51. Cecchi R, Pavesi M, Bartoli L, Brunetti L, Rapicano V: Perineal extramammary Paget disease responsive to topical imiquimod. J Dtsch Dermatol Ges; 2010 Jan;8(1):38-40
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extramammary Paget disease (EMPD) is a rare neoplasm that arises in skin rich in apocrine glands, such as the axillae and anogenital region and usually affects the elderly.
  • In most cases, EMPD is an apocrine carcinoma in situ, but it can be associated with internal malignancy spreading to overlying skin.

  • Genetic Alliance. consumer health - Paget Disease.
  • Genetic Alliance. consumer health - Paget disease, extramammary.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20096058.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


52. Kazakov DV, Magro G, Kutzner H, Spagnolo DV, Yang Y, Zaspa O, Mukensnabl P, Michal M: Spiradenoma and spiradenocylindroma with an adenomatous or atypical adenomatous component: a clinicopathological study of 6 cases. Am J Dermatopathol; 2008 Oct;30(5):436-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 1 case, apocrine secretion was evident in the glandular part of the lesion.
  • As this alteration was limited and fairly well circumscribed within the tumor bulk, we regard it as an "atypical adenomatous component," but we cannot exclude the possibility that this may represent an incipient apocrine carcinoma, despite uneventful follow-up.
  • [MeSH-major] Adenoma / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Diagnosis, Differential. Female. Humans. Keratin-14 / metabolism. Male. Middle Aged. Myoepithelioma / diagnosis. Myoepithelioma / metabolism. Myoepithelioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18806484.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-14
  •  go-up   go-down


53. Kaya H, Bozkurt SU, Erbarut I, Djamgoz MB: Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression. Pathol Res Pract; 2008;204(6):367-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression.
  • The aims of this study were twofold: (i) to determine the occurrence frequency of apocrine carcinoma of the breast (ApBCa) in Turkish breast cancer (BCa) patients; and (ii) to evaluate the expression of estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), gross cystic disease protein-15 (GCDFP-15), c-erbB-2, and p53 in these cases.
  • The results of ApBCa were compared with those of invasive ductal carcinoma not otherwise specified type (IDC-NOS) cases of similar grade.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Steroid / metabolism. Sweat Gland Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Apocrine Glands / metabolism. Apocrine Glands / pathology. Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carrier Proteins / metabolism. Female. Glycoproteins / metabolism. Humans. Immunoenzyme Techniques. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342452.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / PIP protein, human; 0 / Receptors, Steroid; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


54. Kuroki-Suzuki S, Kuroki Y, Nasu K, Nawano S, Moriyama N, Okazaki M: Detecting breast cancer with non-contrast MR imaging: combining diffusion-weighted and STIR imaging. Magn Reson Med Sci; 2007;6(1):21-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interpreted images were evaluated for sensitivity, false negative rate (FN), sensitivity by pT, and sensitivity by background density of the mammary gland.
  • Sensitivities by background density of mammary gland were: fatty/scattered fibroglandular tissue, 95% (20/21) and heterogeneous fibroglandular tissue/mostly fibroglandular tissue, 98% (48/49).
  • Two cases, an intraductal and an apocrine carcinoma, were incorrectly diagnosed by MR imaging.
  • Precise diagnosis of breast cancer is possible with combined DWI and STIR, even in non-contrast MR imaging, regardless of the diameter or background density of mammary gland.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17510539.001).
  • [ISSN] 1347-3182
  • [Journal-full-title] Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine
  • [ISO-abbreviation] Magn Reson Med Sci
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


55. Suzuki T, Miki Y, Takagi K, Hirakawa H, Moriya T, Ohuchi N, Sasano H: Androgens in human breast carcinoma. Med Mol Morphol; 2010 Jun;43(2):75-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgens in human breast carcinoma.
  • Sex steroids play important roles in the development of human breast carcinoma.
  • Androgen receptor (AR) is expressed in a majority of breast carcinoma tissues.
  • However, the significance of androgen actions remains largely unclear in breast carcinoma, differing from estrogen actions.
  • Therefore, in this review, we summarized recent studies on androgens in breast carcinoma.
  • Concentration of a potent androgen, 5alpha-dihydrotestosterone (DHT), was significantly higher in breast carcinoma tissue than in plasma, and DHT is considered to be locally produced from circulating androstenedione by 17beta-hydroxysteroid dehydrogenase type 5 and 5alpha-reductase.
  • Androgens predominantly show antiproliferative effects in breast carcinoma cells, but association between AR status and the clinical outcome of the patient remains controversial, perhaps partly because AR status does not necessarily reflect androgenic action in breast carcinoma.
  • Recently, molecular apocrine breast carcinoma was identified by microarray analysis.
  • Molecular apocrine carcinoma was characterized by being estrogen receptor (ER) negative and AR positive and by being associated with increased androgen signaling and apocrine features.
  • Therefore, androgenic actions may also be involved in apocrine features in breast carcinoma.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1313-20 [18042688.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Jan;93(1):25-34 [15748829.001]
  • [Cites] Endocr Relat Cancer. 2008 Mar;15(1):113-24 [18310280.001]
  • [Cites] Eur J Cancer. 2009 Sep;45 Suppl 1:11-26 [19775601.001]
  • [Cites] Cancer Res. 2009 Aug 1;69(15):6131-40 [19638585.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):936-43 [10706108.001]
  • [Cites] Br J Cancer. 2008 Jan 15;98(1):137-42 [18043578.001]
  • [Cites] Breast. 2005 Feb;14(1):3-10 [15695074.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Mar;13(1):25-9 [15722790.001]
  • [Cites] Mol Cell Endocrinol. 2002 Jul 31;193(1-2):121-8 [12161011.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7610-7 [15492289.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] J Steroid Biochem Mol Biol. 1995 May;52(5):459-67 [7748811.001]
  • [Cites] Med Mol Morphol. 2007 Sep;40(3):121-7 [17874044.001]
  • [Cites] Cancer Control. 2004 Jul-Aug;11(4):217-21 [15284712.001]
  • [Cites] Mol Cell Proteomics. 2008 Oct;7(10):1795-809 [18632593.001]
  • [Cites] Breast Cancer Res Treat. 1988 Oct;12(2):213-25 [3242650.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7604-9 [15492288.001]
  • [Cites] Mol Endocrinol. 2008 Oct;22(10):2215-28 [18417735.001]
  • [Cites] Breast Cancer Res Treat. 1988 Dec;12(3):287-96 [3147727.001]
  • [Cites] J Steroid Biochem Mol Biol. 1995 Jun;52(6):541-6 [7779758.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):725-31 [14608899.001]
  • [Cites] Cancer. 2007 Jan 1;109(1):25-32 [17146782.001]
  • [Cites] J Pathol. 1993 May;170(1):31-5 [8100853.001]
  • [Cites] Endocr J. 2002 Oct;49(5):539-46 [12507272.001]
  • [Cites] Breast Cancer Res Treat. 1985;5(1):67-73 [3978248.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):701-20 [16322318.001]
  • [Cites] Eur J Cancer. 2009 Sep;45 Suppl 1:27-40 [19775602.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4660-71 [15897907.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Aug;100(4-5):129-40 [16806904.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3945-54 [17440110.001]
  • [Cites] Mol Cell Endocrinol. 2004 Apr 15;218(1-2):7-20 [15130507.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3131-5 [2039992.001]
  • [Cites] Cancer. 1984 Dec 1;54(11):2436-40 [6498736.001]
  • [Cites] Int J Cancer. 2007 Jan 15;120(2):285-91 [17066438.001]
  • [Cites] Histopathology. 2003 May;42(5):440-7 [12713620.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7775-82 [16885381.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Feb;128(2):85-90 [11862478.001]
  • [Cites] Mol Cell Endocrinol. 2001 Jan 22;171(1-2):137-49 [11165022.001]
  • [Cites] J Biol Chem. 2005 May 27;280(21):20421-30 [15772083.001]
  • [Cites] Eur J Surg Oncol. 1992 Apr;18(2):112-8 [1582503.001]
  • [Cites] Int J Clin Oncol. 2008 Oct;13(5):431-5 [18946753.001]
  • [Cites] Mol Cell Endocrinol. 2001 Jan 22;171(1-2):77-82 [11165014.001]
  • [Cites] Endocrinology. 2001 Oct;142(10):4331-8 [11564693.001]
  • [Cites] Endocrinology. 1999 Feb;140(2):568-74 [9927279.001]
  • [Cites] Mol Oncol. 2009 Jun;3(3):220-37 [19393583.001]
  • [Cites] J Cell Biochem. 2005 Jul 1;95(4):657-69 [15861399.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):709-16 [15375489.001]
  • [Cites] J Steroid Biochem. 1986 Jun;24(6):1117-25 [3736038.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2250-7 [11344235.001]
  • [Cites] J Clin Pathol. 2002 Jan;55(1):14-6 [11825917.001]
  • [Cites] Eur J Cancer. 1996 Aug;32A(9):1560-5 [8911118.001]
  • [Cites] Med Mol Morphol. 2006 Mar;39(1):8-13 [16575508.001]
  • [Cites] Br J Cancer. 1996 Oct;74(8):1175-80 [8883401.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):277-83 [15860271.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):2797-802 [2032219.001]
  • [Cites] Mol Cell Endocrinol. 2000 Sep 25;167(1-2):139-50 [11000528.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):703-11 [12910513.001]
  • [Cites] Endocr Rev. 2003 Apr;24(2):152-82 [12700178.001]
  • [Cites] Ann N Y Acad Sci. 2009 Feb;1155:25-32 [19250189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] J Steroid Biochem Mol Biol. 2008 Dec;112(4-5):194-200 [18996480.001]
  • (PMID = 20683693.001).
  • [ISSN] 1860-1499
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgens; 0 / Receptors, Estrogen; 08J2K08A3Y / Dihydrotestosterone; EC 1.14.14.1 / Aromatase
  •  go-up   go-down


56. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van't Veer LJ, Peterse JL: Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol; 2008 Oct;216(2):141-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most invasive breast cancers are classified as invasive ductal carcinoma not otherwise specified (IDC NOS), whereas about 25% are defined as histological 'special types'.
  • We aimed to refine the breast cancer classification systems by analysing a series of 11 histological special types [invasive lobular carcinoma (ILC), tubular, mucinous A, mucinous B, neuroendocrine, apocrine, IDC with osteoclastic giant cells, micropapillary, adenoid cystic, metaplastic, and medullary carcinoma] using immunohistochemistry and genome-wide gene expression profiling.
  • Hierarchical clustering analysis confirmed that some histological special types constitute discrete entities, such as micropapillary carcinoma, but also revealed that others, including tubular and lobular carcinoma, are very similar at the transcriptome level.
  • When classified by expression profiling, IDC NOS and ILC contain all molecular breast cancer types (ie luminal, basal-like, HER2+), whereas histological special-type cancers, apart from apocrine carcinoma, are homogeneous and only belong to one molecular subtype.
  • [MeSH-major] Breast Neoplasms / classification. Carcinoma, Ductal, Breast / classification. Gene Expression Regulation, Neoplastic


57. von Bomhard W, Goldschmidt MH, Shofer FS, Perl L, Rosenthal KL, Mauldin EA: Cutaneous neoplasms in pet rabbits: a retrospective study. Vet Pathol; 2007 Sep;44(5):579-88
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Common nonviral epithelial tumors included trichoblastoma (59), squamous cell carcinoma (5), squamous papilloma (4), trichoepithelioma (3), and apocrine carcinoma (3).
  • [MeSH-minor] Adenoma / pathology. Adenoma / veterinary. Animals. Biopsy / veterinary. Carcinoma / pathology. Carcinoma / veterinary. Female. Hamartoma / pathology. Hamartoma / veterinary. Lipoma / pathology. Lipoma / veterinary. Lymphoma / pathology. Lymphoma / veterinary. Male. Melanoma / pathology. Melanoma / veterinary. Retrospective Studies. Sarcoma / pathology. Sarcoma / veterinary. Tumor Virus Infections / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846230.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Haji BE, Das DK, Al-Ayadhy B, Pathan SK, George SG, Mallik MK, Abdeen SM: Fine-needle aspiration cytologic features of four special types of breast cancers: mucinous, medullary, apocrine, and papillary. Diagn Cytopathol; 2007 Jul;35(7):408-16
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration cytologic features of four special types of breast cancers: mucinous, medullary, apocrine, and papillary.
  • In mucinous carcinoma, the frequency of signet ring cells (62.5%), and background pools of mucin (87.5%) were significantly higher than those of duct cell carcinoma (NOS), medullary carcinoma, apocrine carcinoma, and papillary carcinoma (P = 0.0408 to < 0.0001).
  • In medullary carcinomas, lymphomononuclear cell infiltration (100.0%) was observed in significantly higher number of cases than in papillary, mucinous, and apocrine types (P < 0.0001).
  • Further, moderate to marked nuclear pleomorphism (100.0%) and nuclear irregularity (77.8%) was significantly higher than those of mucinous carcinoma and papillary carcinoma (P = 0.0294 to <0.0003).
  • Abnormal apocrine cells and papillary formation, characterizing all the apocrine carcinomas and papillary carcinomas, respectively, were present in significantly lower number in other variants and in duct cell carcinoma (NOS) (P = 0.0002 to <0.0001).
  • Glycogen vacuoles (63.6%) were observed in a significantly higher number of papillary carcinoma as compared to duct cell carcinoma (NOS), apocrine, and medullary carcinomas (P = 0.0047 to 0.0022).
  • The significant parameters differentiating papillary carcinoma and benign papillary lesions were loose cohesive clusters (P = 0.001) and acinar formation by neoplastic cells (P = 0.0237).
  • Histopathology reports available in 36 cases, confirmed the cytodiagnosis of carcinoma in all 35 cases and the benign lesion in one case.
  • Cytological subtyping was confirmed in 13 of 16 special types of carcinomas and all the 15 duct cell carcinoma (NOS).
  • Thus, special and unusual variants of duct cell carcinomas like mucinous, medullary, apocrine, and papillary have specific cytomorphological features, which differentiate them from one another and from duct cell carcinoma (NOS).
  • However, differentiating features between papillary carcinoma and benign papillary lesions were very few in this study.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Apocrine Glands / pathology. Biopsy, Fine-Needle. Breast Neoplasms / pathology. Carcinoma, Medullary / pathology. Carcinoma, Papillary / pathology
  • [MeSH-minor] Carcinoma, Ductal, Breast / pathology. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580344.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Ogiya A, Horii R, Osako T, Ito Y, Iwase T, Eishi Y, Akiyama F: Apocrine metaplasia of breast cancer: clinicopathological features and predicting response. Breast Cancer; 2010 Oct;17(4):290-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine metaplasia of breast cancer: clinicopathological features and predicting response.
  • From our institutional neoadjuvant experience, apocrine carcinoma showed a high correlation with therapeutic effect against breast cancer.
  • We thus considered that apocrine metaplasia (AM) might represent a predictive marker for breast cancer.
  • CONCLUSIONS: Apocrine metaplasia appears to offer an effective predictive marker for anticancer therapy.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / chemistry. Breast Neoplasms / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19789945.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Ki-67 Antigen; 0 / PIP protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Androgen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


60. Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T: Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer; 2010 Apr;17(2):118-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Morphologically, the TN subtype was more frequently classified as solid-tubular carcinoma.
  • Mucinous, tubular, or secretary carcinomas were frequently found in the hormone receptor positive/HER2 negative subtype, while squamous cell carcinoma, spindle cell carcinoma, and metaplastic carcinoma with bone/cartilage metaplasia were very frequently found in the TN group.
  • Apocrine carcinoma was also found very frequently in the TN group.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Humans. Japan. Middle Aged. Prognosis. Receptor, ErbB-2 / metabolism. Registries. Societies, Medical / statistics & numerical data. Young Adult


61. Caldeira JR, Prando EC, Quevedo FC, Neto FA, Rainho CA, Rogatto SR: CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer; 2006;6:48
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The aim of our study was to assess, by Methylation-Specific Polymerase Chain Reaction (MSP), the methylation pattern of the CDH1 gene and its possible correlation with the expression of E-cadherin and other standard immunohistochemical parameters (Her-2, ER, PgR, p53, and K-67) in a series of 79 primary breast cancers (71 infiltrating ductal, 5 infiltrating lobular, 1 metaplastic, 1 apocrine, and 1 papillary carcinoma).
  • RESULTS: CDH1 hypermethylation was observed in 72% of the cases including 52/71 ductal, 4/5 lobular carcinomas and 1 apocrine carcinoma.
  • [MeSH-major] Breast Neoplasms / genetics. Cadherins / genetics. Carcinoma, Ductal, Breast / genetics. Carcinoma, Lobular / genetics. Genes, Tumor Suppressor. Promoter Regions, Genetic / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Relat Cancer. 2001 Jun;8(2):115-27 [11446343.001]
  • [Cites] J Pathol. 1997 Dec;183(4):404-11 [9496256.001]
  • [Cites] Hum Mol Genet. 2001 Dec 15;10(26):3001-7 [11751682.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):441-51 [12013533.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3382-6 [12067979.001]
  • [Cites] Anal Cell Pathol. 2002;24(2-3):69-76 [12446956.001]
  • [Cites] Ann Diagn Pathol. 2002 Dec;6(6):349-51 [12478484.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3413-7 [12960130.001]
  • [Cites] Adv Anat Pathol. 2003 Sep;10(5):278-90 [12973049.001]
  • [Cites] Oncol Rep. 2003 Nov-Dec;10(6):1811-5 [14534701.001]
  • [Cites] Mech Ageing Dev. 2003 Dec;124(10-12):989-98 [14659588.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(1):306-19 [14673164.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:155-63 [15153430.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 25;319(2):697-704 [15178462.001]
  • [Cites] Int J Clin Oncol. 2004 Jun;9(3):154-60 [15221598.001]
  • [Cites] Oncologist. 2004;9(4):361-77 [15266090.001]
  • [Cites] Biochem Pharmacol. 2004 Sep 15;68(6):1187-97 [15313416.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5349-54 [15328171.001]
  • [Cites] Science. 1995 Jan 20;267(5196):386-9 [7824937.001]
  • [Cites] Biotechniques. 1994 Nov;17(5):914-21 [7840973.001]
  • [Cites] J Biol Chem. 1996 Jan 5;271(1):595-602 [8550625.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Oncogene. 1996 Nov 7;13(9):1919-25 [8934538.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Jul;19(3):185-91 [9219000.001]
  • [Cites] J Mol Med (Berl). 1997 Jun;75(6):429-39 [9231883.001]
  • [Cites] Int J Oncol. 1998 Jul;13(1):177-82 [9625819.001]
  • [Cites] Cancer Res. 1998 Jun 15;58(12):2515-9 [9635570.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):333-9 [9708792.001]
  • [Cites] Clin Cancer Res. 1996 May;2(5):805-10 [9816234.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3855-60 [10463569.001]
  • [Cites] Hum Mutat. 1999;14(3):249-55 [10477433.001]
  • [Cites] Br J Cancer. 1957 Sep;11(3):359-77 [13499785.001]
  • [Cites] Oncogene. 1999 Dec 2;18(51):7274-9 [10602481.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2727-32 [10644736.001]
  • [Cites] Eur J Cancer. 2000 Jun;36(9):1098-106 [10854942.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4346-8 [10969774.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4243-8 [11106238.001]
  • [Cites] Am J Clin Pathol. 2001 Jan;115(1):85-98 [11190811.001]
  • [Cites] Genomics. 2000 Dec 15;70(3):273-85 [11161777.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1171-7 [11221848.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):404-8 [11291078.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Apr 1;126(1):39-44 [11343777.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7202-6 [7913748.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):14-8 [15459769.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2156-62 [15788661.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2765-9 [11555590.001]
  • (PMID = 16512896.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins
  • [Other-IDs] NLM/ PMC1523210
  •  go-up   go-down


62. Elayat G, Selim AG, Wells CA: Cell turnover in apocrine metaplasia and apocrine adenosis of the breast. Ann Diagn Pathol; 2010 Feb;14(1):1-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell turnover in apocrine metaplasia and apocrine adenosis of the breast.
  • Apocrine metaplasia (APM) is a common finding in the breast of postmenopausal women and is seen in a broad spectrum of lesions ranging from microscopic cysts to invasive apocrine carcinoma.
  • Apocrine metaplasia within sclerosing adenosis is known as apocrine adenosis (AA) and is considered a benign lesion of the breast.
  • Apocrine metaplasia and AA have been the subject of many studies; however, little is known about the dynamics of cell turnover in these lesions.
  • [MeSH-major] Apocrine Glands / pathology. Breast / pathology. Breast Neoplasms / pathology. Fibrocystic Breast Disease / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Apoptosis. Biomarkers, Tumor / metabolism. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cell Division. Epithelium / metabolism. Epithelium / pathology. Female. Humans. In Situ Nick-End Labeling. Ki-67 Antigen / metabolism. Metaplasia. Myeloid Cell Leukemia Sequence 1 Protein. Proto-Oncogene Proteins c-bcl-2 / metabolism. Telomerase / metabolism. bcl-2 Homologous Antagonist-Killer Protein / metabolism. bcl-X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20123450.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAK1 protein, human; 0 / BCL2L1 protein, human; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2 Homologous Antagonist-Killer Protein; 0 / bcl-X Protein; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


63. Usui K, Ochiai T, Abe I, Nishio H, Togo K, Yamagata M: Apocrine gland carcinoma of the mammary skin concomitant with pagetoid phenomenon. J Dermatol; 2010 Apr;37(4):350-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine gland carcinoma of the mammary skin concomitant with pagetoid phenomenon.
  • We reported a 52-year-old woman with an apocrine gland carcinoma of the mammary skin concomitant with pagetoid phenomenon.
  • Our diagnosis revealed that the nodule was an apocrine gland carcinoma and the intraepidermal neoplastic cells with pagetoid spread in the pigmented plaque were derived from the apocrine gland carcinoma.
  • No Paget's cells were detected in the right nipple, and no tumor cells were observed in the sentinel lymph node and underlying mammary gland tissue.
  • They showed that both intraepidermal neoplastic cells with pagetoid spread and tumor cells of the apocrine gland carcinoma were positive with cytokeratin-7 and human epidermal growth factor receptor-2 (HER-2)/neu overexpression.
  • The results of the present study conclude that the intraepithelial spread of tumor cells in the mammary skin distant from the nipple occurred as a pagetoid phenomenon, and that HER-2 may have a key role in pagetoid phenomenon of an underlying apocrine gland carcinoma, as well as in mammary Paget's disease.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / pathology. Carcinoma / pathology. Paget's Disease, Mammary / pathology. Sweat Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20507405.001).
  • [ISSN] 1346-8138
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-7; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


64. Robson A, Lazar AJ, Ben Nagi J, Hanby A, Grayson W, Feinmesser M, Granter SR, Seed P, Warneke CL, McKee PH, Calonje E: Primary cutaneous apocrine carcinoma: a clinico-pathologic analysis of 24 cases. Am J Surg Pathol; 2008 May;32(5):682-90
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous apocrine carcinoma: a clinico-pathologic analysis of 24 cases.
  • Primary cutaneous apocrine carcinoma is a rare malignancy.
  • This study of 24 examples suggests that the prognosis is not always poor and that grading criteria devised for breast carcinoma may have utility in this group of malignancies.
  • [MeSH-major] Adenocarcinoma / pathology. Apocrine Glands / pathology. Sweat Gland Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2009 Jan;33(1):155-7 [18971780.001]
  • (PMID = 18347508.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


65. Spugnini EP, Dotsinsky I, Mudrov N, De Luca A, Codini C, Citro G, D'Avino A, Baldi A: Successful rescue of an apocrine gland carcinoma metastatic to the cervical lymph nodes by mitoxantrone coupled with trains of permeabilizing electrical pulses (electrochemotherapy). In Vivo; 2008 Jan-Feb;22(1):51-3
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful rescue of an apocrine gland carcinoma metastatic to the cervical lymph nodes by mitoxantrone coupled with trains of permeabilizing electrical pulses (electrochemotherapy).
  • Canine apocrine gland carcinoma is a locally aggressive neoplasm that can occasionally lead to metastatic spread, thus mimicking the behavior of their human counterpart.
  • Electrochemotherapy is a safe and efficacious therapy for metastatic carcinoma and warrants further investigation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Apocrine Glands / pathology. Carcinoma / veterinary. Electrochemotherapy / veterinary. Mitoxantrone / therapeutic use. Sweat Gland Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396782.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


66. Roy S, Shafi NQ, Rose MG: Locally recurrent and metastatic apocrine-gland carcinoma in an elderly man. Nat Clin Pract Oncol; 2007 Jan;4(1):56-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally recurrent and metastatic apocrine-gland carcinoma in an elderly man.
  • DIAGNOSIS: Carcinoma of the axillary apocrine gland.
  • [MeSH-major] Adenocarcinoma / pathology. Apocrine Glands. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17183356.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Guerriero S, Ruffolo C, Lombardi AR, Tirone A, Tirone G: Recurrent pleural effusion and pulmonary metastases from a cutaneous apocrine tumour of the axilla. Acta Chir Belg; 2007 Nov-Dec;107(6):697-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent pleural effusion and pulmonary metastases from a cutaneous apocrine tumour of the axilla.
  • Sweat gland carcinomas are very rare and they are differentiated between tumours of apocrine or eccrine origin.
  • The axilla is the most common site for apocrine gland carcinoma for its great abundance of these glands.
  • There are no recommendations in literature regarding appropriate treatment schedules for apocrine gland carcimonas in advanced stages.
  • We report a case of recurrent left pleural effusion in a 76-year old man with metastatic cutaneous apocrine tumour of the right axilla.
  • We describe the clinical and histological features, with management options and a review of the relevant literature on apocrine gland carcinoma.
  • [MeSH-major] Apocrine Glands. Axilla. Lung Neoplasms / secondary. Pleural Effusion / etiology. Skin Neoplasms / pathology. Sweat Gland Neoplasms / complications. Sweat Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18274189.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


68. Unal E, Firat A, Gunes P, Kilicoglu G, Gulkilik A, Titiz I: Apocrine carcinoma of the breast: clinical, radiologic, and pathologic correlation. Breast J; 2007 Nov-Dec;13(6):617-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine carcinoma of the breast: clinical, radiologic, and pathologic correlation.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / diagnosis. Hair Follicle / pathology. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / pathology. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17983408.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Bezić J, Forempoher G, Poljicanin A, Gunjaca G: Apocrine adenoma of the breast coexistent with invasive carcinoma. Pathol Res Pract; 2007;203(11):809-12
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine adenoma of the breast coexistent with invasive carcinoma.
  • We describe a case of apocrine adenoma with simultaneous occurrence of invasive ductal carcinoma in the breast of a 53-year-old woman.
  • Apocrine adenoma affecting the breast is very rare.
  • The lesion is composed of back-to-back ducts and papillary fronds covered with apocrine cells, and it is sharply demarcated from the surrounding breast tissue.
  • The ultrasound also revealed in the surrounding breast parenchyma an additional abnormal finding suggestive of carcinoma.
  • Histologic examination of the excised specimen showed that the hypoechogenic nodule represented an apocrine adenoma in proximity to the invasive ductal breast carcinoma.
  • [MeSH-major] Adenoma, Sweat Gland / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Neoplasms, Multiple Primary / pathology. Sweat Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17936522.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


70. Zagorianakou P, Zagorianakou N, Stefanou D, Makrydimas G, Agnantis NJ: The enigmatic nature of apocrine breast lesions. Virchows Arch; 2006 May;448(5):525-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The enigmatic nature of apocrine breast lesions.
  • Epithelial cells of fetal breast glandular structures, at the third trimester of pregnancy (28 weeks), produce GCDFP-15, in the absence of specific apocrine morphology.
  • Apocrine epithelium of the breast may be a normal process of differentiation rather than a result of metaplasia, and it has been demonstrated that it is estrogen-receptor, progesterone-receptor and bcl-2 negative, but androgen-receptor (AR) positive.
  • The significance of AR expression in apocrine epithelium is uncertain.
  • Apocrine epithelium is seen in a wide spectrum of breast entities, ranging from benign lesions to invasive carcinoma.
  • Apocrine epithelium may reflect instability of the breast epithelium, creating an environment favouring further oncogenic alterations.
  • In the last decade, several lines of evidence support the idea that some breast benign epithelial apocrine lesions are clonal lesions and may be considered as truly pre-malignant or precursors of breast carcinoma.
  • Apocrine changes in many cases do not present any diagnostic difficulty; on the other hand, apocrine proliferations with cytologic atypia can be particularly difficult and challenging.
  • The purpose of this study is to collect and highlight the areas of consensus in the literature as well as the controversial areas concerning the apocrine epithelium of the breast.
  • [MeSH-major] Apocrine Glands / cytology. Breast / cytology. Breast Neoplasms / physiopathology. Cell Transformation, Neoplastic / metabolism. Epithelial Cells / cytology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1990 Mar;26(3):277-81 [2141484.001]
  • [Cites] Arch Pathol. 1970 May;89(5):446-52 [4191043.001]
  • [Cites] Hum Pathol. 1989 Jun;20(6):504-17 [2656496.001]
  • [Cites] Br J Cancer. 1991 Nov;64(5):953-5 [1931623.001]
  • [Cites] Ann N Y Acad Sci. 1990;586:161-73 [2192632.001]
  • [Cites] Mod Pathol. 1994 Oct;7(8):813-8 [7838835.001]
  • [Cites] Cancer Res. 1988 Oct 15;48(20):5860-3 [2971432.001]
  • [Cites] Histopathology. 1980 Jul;4(4):413-28 [7429430.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Apr;5(2):119-37 [11149569.001]
  • [Cites] J Pathol. 1975 Apr;115(4):211-4 [1159568.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1798-802 [9351550.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):146-51 [3965932.001]
  • [Cites] Anticancer Res. 1988 Nov-Dec;8(6):1217-22 [3064712.001]
  • [Cites] Hum Pathol. 1981 Aug;12(8):751-3 [7286970.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):13-8 [10658905.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):323-9 [10880402.001]
  • [Cites] J Pathol. 2005 Jan;205(2):248-54 [15641021.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):164-8 [8119716.001]
  • [Cites] Am J Surg. 1989 Jun;157(6):577-80; discussion 581 [2499206.001]
  • [Cites] Cancer. 1975 Feb;35(2):499-506 [1111924.001]
  • [Cites] Cancer Res. 1986 Jul;46(7):3728-33 [3486713.001]
  • [Cites] BMJ. 1997 Mar 29;314(7085):925-8 [9099114.001]
  • [Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]
  • [Cites] Cancer Detect Prev. 1992;16(2):89-92 [1600525.001]
  • [Cites] Virchows Arch. 1994;425(5):459-65 [7850069.001]
  • [Cites] Am J Clin Pathol. 1990 Oct;94(4):371-7 [2171320.001]
  • [Cites] Arch Dis Child. 1988 Feb;63(2):136-9 [3348660.001]
  • [Cites] Hum Pathol. 1993 Feb;24(2):173-81 [8381766.001]
  • [Cites] Acta Cytol. 1989 Jan-Feb;33(1):104-8 [2644742.001]
  • [Cites] Ann N Y Acad Sci. 1990;586:121-36 [2141455.001]
  • [Cites] Cancer. 1980 Dec 1;46(11):2463-71 [6254632.001]
  • [Cites] Acta Cytol. 2003 Mar-Apr;47(2):265-9 [12685199.001]
  • [Cites] Am J Surg Pathol. 1983 Jul;7(5):451-61 [6351647.001]
  • [Cites] Cancer. 1971 Mar;27(3):643-50 [5549498.001]
  • [Cites] Hum Pathol. 1989 Mar;20(3):281-7 [2542151.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2529-37 [8640702.001]
  • [Cites] Mod Pathol. 1990 May;3(3):373-6 [2362943.001]
  • [Cites] Lab Invest. 1996 Jan;74(1):129-35 [8569175.001]
  • [Cites] N Engl J Med. 1982 Oct 14;307(16):1010-4 [7110289.001]
  • [Cites] J Clin Pathol. 1995 Aug;48(8):737-42 [7560201.001]
  • [Cites] Pathol Res Pract. 1997;193(11-12):753-8 [9521507.001]
  • [Cites] Cancer Res. 1987 Aug 1;47(15):4160-4 [3607757.001]
  • [Cites] Eur J Gynaecol Oncol. 1992;13(4):309-15 [1325346.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):207-14 [11141494.001]
  • [Cites] Maturitas. 2004 Sep 24;49(1):2-15 [15351091.001]
  • [Cites] Cancer. 1968 Apr;21(4):756-63 [4296681.001]
  • [Cites] Clin Cancer Res. 1995 Mar;1(3):261-7 [9815981.001]
  • [Cites] Breast Cancer. 2002;9(1):43-9 [12196721.001]
  • [Cites] Morphol Embryol (Bucur). 1990 Jan-Mar;36(1):43-7 [2149412.001]
  • [Cites] Cancer. 1968 Sep;22(3):587-600 [5673237.001]
  • [Cites] J Biol Chem. 1985 Sep 15;260(20):11307-13 [2863272.001]
  • [Cites] Virchows Arch. 1997 Sep;431(3):205-9 [9334842.001]
  • [Cites] Am J Clin Pathol. 2000 May;113(5 Suppl 1):S3-18 [11993707.001]
  • [Cites] Radiology. 1994 Jun;191(3):633-8 [8184039.001]
  • [Cites] J Clin Pathol. 1999 Nov;52(11):838-41 [10690175.001]
  • [Cites] J Pathol. 2002 Mar;196(3):287-91 [11857491.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Jan 28;288(6413):275-8 [6419893.001]
  • [Cites] Int J Cancer. 1992 Oct 21;52(4):581-4 [1399140.001]
  • [Cites] Arch Pathol Lab Med. 1986 Mar;110(3):171-3 [3606334.001]
  • [Cites] Hum Pathol. 1984 Feb;15(2):134-40 [6365733.001]
  • [Cites] Breast J. 2003 Jul-Aug;9(4):335-6 [12846876.001]
  • [Cites] Lancet. 1999 May 22;353(9166):1742-5 [10347986.001]
  • [Cites] Acta Cytol. 1996 Mar-Apr;40(2):247-51 [8629406.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jan;5(1):29-32 [8770463.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):381-6 [3557440.001]
  • [Cites] Surg Gynecol Obstet. 1949 Jan;88(1):1-10 [18104212.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):449-55 [12447674.001]
  • [Cites] Mod Pathol. 1991 Jan;4(1):1-5 [2020652.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):703-11 [12910513.001]
  • [Cites] Am J Obstet Gynecol. 1980 Sep 1;138(1):25-32 [7416203.001]
  • [Cites] Mod Pathol. 1990 Jul;3(4):449-54 [2170971.001]
  • [Cites] J Invest Dermatol. 1968 Mar;50(3):238-43 [4384574.001]
  • [Cites] Diagn Cytopathol. 1988 Mar;4(1):62-6 [3378488.001]
  • [Cites] J Natl Cancer Inst. 1978 Oct;61(4):1055-63 [279711.001]
  • [Cites] Pathol Oncol Res. 2002;8(2):151-2 [12172583.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):860-921 [11237011.001]
  • [Cites] Cancer Detect Prev. 2001;25(3):262-7 [11425268.001]
  • (PMID = 16570182.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 97
  •  go-up   go-down


71. Seethala RR, Richmond JA, Hoschar AP, Barnes EL: New variants of epithelial-myoepithelial carcinoma: oncocytic-sebaceous and apocrine. Arch Pathol Lab Med; 2009 Jun;133(6):950-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New variants of epithelial-myoepithelial carcinoma: oncocytic-sebaceous and apocrine.
  • CONTEXT: Recently described variants of epithelial-myoepithelial carcinoma have not been well characterized but raise a distinct set of differential diagnostic considerations than the classic type.
  • OBJECTIVE: To report a detailed analysis of oncocytic-sebaceous epithelial-myoepithelial carcinoma (OEMCa) and a similar, but novel, variant, apocrine epithelial-myoepithelial carcinoma (ApEMCa).
  • CONCLUSIONS: Oncocytic-sebaceous epithelial-myoepithelial carcinoma and ApEMCa should be considered in the differential diagnosis of oncocytic/oncocytoid salivary gland tumors.
  • Oncocytic-sebaceous epithelial-myoepithelial carcinoma morphology may reflect a senescent phenotype, similar to other oncocytic lesions.
  • The ductal component of ApEMCa shares some similarities with salivary duct carcinoma and supports the notion that epithelial-myoepithelial carcinoma can serve as the progenitor tumor for hybrid tumors.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Apocrine Glands / pathology. Carcinoma / pathology. Myoepithelioma / pathology. Parotid Neoplasms / pathology


72. O'Malley FP, Bane A: An update on apocrine lesions of the breast. Histopathology; 2008 Jan;52(1):3-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An update on apocrine lesions of the breast.
  • Apocrine change occurs in a spectrum of benign lesions in the female breast and is also demonstrated in a subgroup of in situ and invasive carcinomas.
  • Recent research has focused on the molecular phenotype of both benign and malignant apocrine lesions.
  • This review will briefly summarize the morphological characteristics and risk associations of the spectrum of apocrine proliferations, but will focus on the updated molecular studies of both in situ and invasive apocrine carcinomas.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / pathology. Carcinoma in Situ / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18171412.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 61
  •  go-up   go-down


73. Wells CA, El-Ayat GA: Non-operative breast pathology: apocrine lesions. J Clin Pathol; 2007 Dec;60(12):1313-20
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-operative breast pathology: apocrine lesions.
  • Apocrine metaplasia is a very common finding in the female breast after the age of 25.
  • This, however, is only really the case in apocrine sweat glands of the axilla and in the peri-areolar apocrine glands.
  • The apocrine cell does, however, contribute to a number of different breast lesions, some of which are very taxing diagnostically; apocrine variants of both in-situ and invasive cancer are encountered.
  • This review considers the common apocrine metaplastic lesions seen in fibrocystic change as well as apocrine adenoma, apocrine change within sclerosing adenosis, atypical apocrine lesions and apocrine malignancies.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adenoma / pathology. Biopsy. Breast / pathology. Carcinoma, Ductal, Breast / pathology. Female. Fibrocystic Breast Disease / pathology. Humans. Hyperplasia / pathology. Metaplasia / pathology. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1999 Nov;52(11):838-41 [10690175.001]
  • [Cites] APMIS. 2006 May;114(5):352-8 [16725011.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):207-14 [11141494.001]
  • [Cites] Hum Pathol. 2001 May;32(5):487-93 [11381366.001]
  • [Cites] Histopathology. 2001 Aug;39(2):198-202 [11493337.001]
  • [Cites] J Clin Pathol. 2002 Jan;55(1):14-6 [11825917.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):449-55 [12447674.001]
  • [Cites] Breast J. 2003 Jul-Aug;9(4):335-6 [12846876.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):703-11 [12910513.001]
  • [Cites] Adv Anat Pathol. 2004 Jan;11(1):1-9 [14676636.001]
  • [Cites] Cancer. 1968 Apr;21(4):756-63 [4296681.001]
  • [Cites] Cancer. 1976 Jun;37(6):2891-905 [949710.001]
  • [Cites] Cancer. 1980 Dec 1;46(11):2463-71 [6254632.001]
  • [Cites] Surg Gynecol Obstet. 1981 Apr;152(4):437-40 [7209771.001]
  • [Cites] Am J Pathol. 1983 Feb;110(2):105-12 [6130702.001]
  • [Cites] Am J Surg Pathol. 1983 Jul;7(5):451-61 [6351647.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):146-51 [3965932.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Sep;21(9):1047-50 [4065177.001]
  • [Cites] Am J Pathol. 1986 Jun;123(3):532-41 [3717305.001]
  • [Cites] Ann N Y Acad Sci. 1986;464:262-74 [3524352.001]
  • [Cites] Hum Pathol. 1987 Apr;18(4):381-6 [3557440.001]
  • [Cites] Histopathology. 1987 Jun;11(6):603-10 [3305282.001]
  • [Cites] Histopathology. 1987 Mar;11(3):305-15 [2828217.001]
  • [Cites] Br J Cancer. 1987 Dec;56(6):814-9 [2829956.001]
  • [Cites] Breast Cancer Res Treat. 1988 Sep;12(1):37-44 [2848603.001]
  • [Cites] Hum Pathol. 1989 Mar;20(3):281-7 [2542151.001]
  • [Cites] Ann N Y Acad Sci. 1990;586:161-73 [2192632.001]
  • [Cites] Ann N Y Acad Sci. 1990;586:188-97 [2357000.001]
  • [Cites] Am J Clin Pathol. 1990 Oct;94(4):371-7 [2171320.001]
  • [Cites] Am J Surg Pathol. 1991 Jul;15(7):687-94 [2058763.001]
  • [Cites] Br J Cancer. 1991 Nov;64(5):953-5 [1931623.001]
  • [Cites] Hum Pathol. 1992 Jun;23(6):655-62 [1592388.001]
  • [Cites] Cancer Detect Prev. 1992;16(2):99-106 [1600527.001]
  • [Cites] CMAJ. 1992 Jul 1;147(1):45-9 [1393887.001]
  • [Cites] N Engl J Med. 1994 Jul 7;331(1):10-5 [8202095.001]
  • [Cites] Cytopathology. 1994 Apr;5(2):123-8 [8038424.001]
  • [Cites] Mod Pathol. 1994 Oct;7(8):813-8 [7838835.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2529-37 [8640702.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jan;5(1):29-32 [8770463.001]
  • [Cites] BMJ. 1997 Mar 29;314(7085):925-8 [9099114.001]
  • [Cites] Hum Pathol. 1997 Aug;28(8):967-73 [9269834.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1798-802 [9351550.001]
  • [Cites] Pathol Res Pract. 1997;193(11-12):753-8 [9521507.001]
  • [Cites] Virchows Arch. 1998 Dec;433(6):505-9 [9870682.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1053-5 [9870852.001]
  • [Cites] Lancet. 1999 May 22;353(9166):1742-5 [10347986.001]
  • [Cites] Breast. 2005 Feb;14(1):3-10 [15695074.001]
  • [Cites] Breast. 2005 Feb;14(1):37-41 [15695079.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R296-305 [15743508.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4660-71 [15897907.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2935-44 [16631754.001]
  • [Cites] J Pathol. 2000 Jun;191(2):138-42 [10861572.001]
  • (PMID = 18042688.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 62
  • [Other-IDs] NLM/ PMC2095572
  •  go-up   go-down


74. Kazakov DV, Kutzner H, Spagnolo DV, Kempf W, Zelger B, Mukensnabl P, Michal M: Sebaceous differentiation in poroid neoplasms: report of 11 cases, including a case of metaplastic carcinoma associated with apocrine poroma (sarcomatoid apocrine porocarcinoma). Am J Dermatopathol; 2008 Feb;30(1):21-6
Zurich Open Access Repository and Archive. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sebaceous differentiation in poroid neoplasms: report of 11 cases, including a case of metaplastic carcinoma associated with apocrine poroma (sarcomatoid apocrine porocarcinoma).
  • We describe 11 poroid neoplasms with sebaceous differentiation, including a metaplastic (sarcomatoid) carcinoma arising in association with an apocrine poroma.
  • The single carcinoma was an ulcerated oval to spindle cell neoplasm surrounded laterally by the residuum of a poroma containing groups of sebocytes.
  • The epithelial islands of the poroma were prominently keratinized and blended gradually with the pleomorphic cells of the metaplastic carcinoma that immunohistochemically stained focally for cytokeratins and simultaneously showed strong vimentin expression.
  • Occurrence of metaplastic carcinoma in association with apocrine poroma is a rare event which indicates the existence of a malignant counterpart of the latter entity, which can be descriptively referred to as "sarcomatoid apocrine porocarcinoma. "
  • [MeSH-major] Adenoma, Sweat Gland / pathology. Neoplasms, Multiple Primary / pathology. Sarcoma / pathology. Sebaceous Glands / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212539.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Adamski H, Le Lan J, Chevrier S, Cribier B, Watier E, Chevrant-Breton J: Primary cutaneous cribriform carcinoma: a rare apocrine tumour. J Cutan Pathol; 2005 Sep;32(8):577-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous cribriform carcinoma: a rare apocrine tumour.
  • BACKGROUND: Primary cutaneous cribriform carcinoma (PCCC) is a rare apocrine tumour occurring in middle-aged people.
  • Differential diagnoses, including cutaneous metastasis of adenocarcinoma, adenoid basal cell carcinoma and adenoid cystic carcinoma, are discussed.
  • [MeSH-major] Adenocarcinoma / pathology. Apocrine Glands / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115058.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


76. Visscher DW: Apocrine ductal carcinoma in situ involving a sclerosing lesion with adenosis: report of a case. Arch Pathol Lab Med; 2009 Nov;133(11):1817-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine ductal carcinoma in situ involving a sclerosing lesion with adenosis: report of a case.
  • Apocrine metaplasia is a ubiquitous component of the mammary fibrocystic change spectrum.
  • Although mostly associated with cysts, apocrine metaplasia can also present as a proliferative lesion, rarely with cytologic atypism.
  • Apocrine atypia is characterized by 3-fold nuclear enlargement, multiple nucleoli, and hyperchromatism and generally arises in florid adenosis or radial sclerosing lesions.
  • Dramatic apocrine atypia may be very difficult to distinguish from apocrine ductal carcinoma in situ.
  • The latter is distinguished from apocrine atypia by greater extent of the lesion (>0.4 cm) and the presence of greater nuclear pleomorphism with nuclear membrane irregularity.
  • The clinical significance of apocrine atypia is poorly understood and reflects the lack of published outcome studies.
  • Herein, I report a case in which apocrine ductal carcinoma in situ presented as "atypical apocrine adenosis" in a needle core breast biopsy.
  • It illustrates the problem of assessing apocrine atypia and apocrine ductal carcinoma in situ in small samples.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Fibrocystic Breast Disease / pathology. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886717.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Simeonov RS, Simeonova GP: Use of quantitative analysis as a method for differentiation between canine cutaneous apocrine adenomas and apocrine carcinomas on cytological smears. J Vet Med A Physiol Pathol Clin Med; 2007 Nov;54(9):542-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of quantitative analysis as a method for differentiation between canine cutaneous apocrine adenomas and apocrine carcinomas on cytological smears.
  • The results indicated an increase in the mean values of investigated parameters from canine cutaneous apocrine adenomas (MNA, 75.65+/-2.22; MNP, 31.05+/-0.55; MND, 9.62+/-0.14; NR, 1.10+/-0.009) to canine cutaneous apocrine carcinomas (MNA, 88.78+/-11.29; MNP, 34.38+/-2.43; MND, 10.43+/-0.76; NR, 1.21+/-0.07).
  • The statistical differences between investigated parameters (P<0.01) were also found between the metastasizing apocrine carcinomas and all other examined carcinomas.
  • [MeSH-major] Adenoma / veterinary. Apocrine Glands / cytology. Carcinoma / veterinary. Cell Nucleus / pathology. Dog Diseases / pathology. Sweat Gland Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931233.001).
  • [ISSN] 0931-184X
  • [Journal-full-title] Journal of veterinary medicine. A, Physiology, pathology, clinical medicine
  • [ISO-abbreviation] J Vet Med A Physiol Pathol Clin Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


78. Masood S, Rosa M: The challenge of apocrine proliferations of the breast: a morphologic approach. Pathol Res Pract; 2009;205(3):155-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The challenge of apocrine proliferations of the breast: a morphologic approach.
  • Apocrine phenotype in breast is common and can be seen in a broad spectrum of lesions ranging from simple cyst to infiltrating carcinoma.
  • The majority of apocrine lesions of the breast are benign in nature and do not represent a diagnostic challenge; however, there are a few that can cause diagnostic problems, such as the case of apocrine proliferations with atypia and low-grade apocrine ductal carcinoma in situ.
  • Furthermore, the role of atypical apocrine proliferations in the pathway to infiltrating carcinoma is still uncertain, and studies with long-term clinical follow-up are necessary to clarify and understand the significance of these apocrine lesions of the breast.
  • The purpose of this article is to review the most recent literature concerning apocrine lesions, with emphasis on borderline apocrine proliferations.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / pathology. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147303.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 32
  •  go-up   go-down


79. Seal M, Wilson C, Naus GJ, Chia S, Bainbridge TC, Hayes MM: Encapsulated apocrine papillary carcinoma of the breast--a tumour of uncertain malignant potential: report of five cases. Virchows Arch; 2009 Dec;455(6):477-83
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Encapsulated apocrine papillary carcinoma of the breast--a tumour of uncertain malignant potential: report of five cases.
  • Five cases of an unusual encapsulated apocrine papillary tumour are reported.
  • The key histological features are similar to those of classical encapsulated papillary carcinoma in that myoepithelial cells were absent within the papillary structures and at the periphery of the cyst.
  • All were pure apocrine in type and showed variable degrees of cytological atypia and mitotic activity.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Papillary / pathology
  • [MeSH-minor] Adult. Aged, 80 and over. Apocrine Glands / pathology. Breast / pathology. Female. Humans. Immunohistochemistry. Mammography. Middle Aged. Ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1313-20 [18042688.001]
  • [Cites] Clin Radiol. 1997 Nov;52(11):865-8 [9392466.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):1002-7 [16861972.001]
  • [Cites] Mod Pathol. 1994 Oct;7(8):813-8 [7838835.001]
  • [Cites] AJR Am J Roentgenol. 2004 Nov;183(5):1516 [15505330.001]
  • [Cites] Am J Clin Pathol. 2009 Feb;131(2):228-42 [19141383.001]
  • [Cites] Adv Anat Pathol. 2004 Jan;11(1):1-9 [14676636.001]
  • [Cites] Histopathology. 2001 Aug;39(2):198-202 [11493337.001]
  • [Cites] Am J Surg Pathol. 2009 Feb;33(2):227-32 [18936688.001]
  • [Cites] Histopathology. 2009 Feb;54(3):348-54 [19236511.001]
  • [Cites] Indian J Pathol Microbiol. 2004 Apr;47(2):268-70 [16295496.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1097-104 [9781648.001]
  • [Cites] Adv Anat Pathol. 2007 Mar;14(2):93-107 [17471116.001]
  • [Cites] Am J Clin Pathol. 2005 Jan;123(1):36-44 [15762278.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):164-8 [8119716.001]
  • [Cites] Adv Anat Pathol. 2007 Mar;14(2):108-19 [17471117.001]
  • [Cites] Am J Surg Pathol. 1983 Jul;7(5):451-61 [6351647.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2529-37 [8640702.001]
  • [Cites] Hum Pathol. 2001 May;32(5):487-93 [11381366.001]
  • [Cites] Ceylon Med J. 1997 Jun;42(2):104-5 [9257474.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):82-90 [12502930.001]
  • [Cites] Histopathology. 2008 Jan;52(1):20-9 [18171414.001]
  • [Cites] Int J Surg Pathol. 2007 Apr;15(2):143-7 [17478767.001]
  • [Cites] Am J Surg. 2007 Oct;194(4):497-500 [17826064.001]
  • [Cites] Histopathology. 2001 Mar;38(3):221-4 [11260302.001]
  • [Cites] Mod Pathol. 1989 Nov;2(6):569-76 [2479944.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jan;5(1):29-32 [8770463.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1076-91 [15252316.001]
  • [Cites] Mod Pathol. 1991 Jan;4(1):1-5 [2020652.001]
  • [Cites] Histopathology. 2008 Jan;52(2):253-5 [18184276.001]
  • [Cites] Cancer. 1977 Apr;39(4):1689-92 [851947.001]
  • [Cites] Hum Pathol. 1994 Aug;25(8):802-9 [8056421.001]
  • (PMID = 19862552.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


80. Obaidat NA, Awamleh AA, Ghazarian DM: Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region. Eur J Dermatol; 2006 Sep-Oct;16(5):576-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region.
  • Histologically, the excised lesion showed features of tubulopapillary apocrine hidradenoma, with an area showing features of carcinoma in situ.
  • Similar to vulvar lesions, peri-anal apocrine tumours are believed to arise in mammary like glands (MLGs).
  • To the best of our knowledge, this is the first description of a peri-anal adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Sweat Gland / pathology. Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Sweat Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101482.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


81. Weinreb I, Tabanda-Lichauco R, Van der Kwast T, Perez-Ordoñez B: Low-grade intraductal carcinoma of salivary gland: report of 3 cases with marked apocrine differentiation. Am J Surg Pathol; 2006 Aug;30(8):1014-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade intraductal carcinoma of salivary gland: report of 3 cases with marked apocrine differentiation.
  • Low-grade intraductal carcinomas (LG-IDCs) of salivary gland are rare neoplasms that resemble atypical ductal hyperplasia or LG-IDCs of the breast.
  • Herein, we describe 3 additional cases of LG-IDCs, 2 were pure intraductal carcinomas, although 1 demonstrated increasing cytologic atypia and progression to an invasive adenosquamous carcinoma.
  • The intraductal component in all cases exhibited a remarkable degree of apocrine differentiation.
  • Extensive apocrine differentiation, expression of ARs, CK7, and CK19, and progression to a widely invasive carcinoma after a long clinical latency have not been reported in LG-IDCs previously.
  • These tumors share some histopathologic features with salivary duct carcinoma including apocrine differentiation, and expression of ARs and BRST-2.
  • The terms "low-grade salivary duct carcinomas" and "low-grade cribriform cystadenocarcinomas" should be abandoned in favor of LG-IDC of salivary gland, which better reflects their predominantly noninvasive, intraductal nature.
  • [MeSH-major] Apocrine Glands / pathology. Carcinoma, Ductal / metabolism. Carcinoma, Ductal / pathology. Salivary Gland Neoplasms / metabolism. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasms, Multiple Primary / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861974.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


82. Obredor C, Palermo M, Zorraquín C, Albertengo JC: [Perineal suppurative hidradenitis and carcinoma. A case report]. Acta Gastroenterol Latinoam; 2009 Dec;39(4):278-81
MedlinePlus Health Information. consumer health - Hidradenitis Suppurativa.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Perineal suppurative hidradenitis and carcinoma. A case report].
  • [Transliterated title] Hidradenitis supurativa de localización perianal y carcinoma. Presentación de un caso.
  • Suppurative hidradenitis is a chronic inflammatory process that involves apocrine glands of the axial, inguinal and perianal region.
  • The pathology showed an epidermoid carcinoma.
  • [MeSH-major] Anus Neoplasms / complications. Carcinoma, Squamous Cell / complications. Hidradenitis Suppurativa / complications

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20178258.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


83. Murali R, Salisbury E, Pathmanathan N: Histiocytoid change in breast carcinoma: a report of 3 cases with an unusual cytomorphologic pattern of apocrine change. Acta Cytol; 2006 Sep-Oct;50(5):548-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histiocytoid change in breast carcinoma: a report of 3 cases with an unusual cytomorphologic pattern of apocrine change.
  • BACKGROUND: Breast carcinomas composed predominantly or exclusively of cells with foamy and/or granular cytoplasm have been termed histiocytoid breast carcinoma.
  • Core biopsies of 2 cases showed a typical Indian file pattern of invasive lobular carcinoma, while the third case was composed of sheets of discohesive histiocytoid cells admixed with a prominent lymphoid infiltrate.
  • CONCLUSION: HBC represents an unusual morphologic pattern of apocrine change that may be seen in lobular and ductal breast carcinomas.
  • [MeSH-major] Apocrine Glands / pathology. Breast / pathology. Breast Neoplasms / diagnosis. Carcinoma / diagnosis. Epithelial Cells / pathology. Histiocytes / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Acta Cytol. 2006 Nov-Dec;50(6):158A
  • (PMID = 17017444.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


84. Bhargava R, Beriwal S, Striebel JM, Dabbs DJ: Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR. Appl Immunohistochem Mol Morphol; 2010 Mar;18(2):113-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
  • The most striking morphologic feature associated with ERBB2 tumors was the presence of apocrine differentiation seen in 7 of 8 (88%) cases.
  • We conclude that tumors with apocrine differentiation are most often of ERBB2 type.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801938.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-5; 0 / Keratin-6; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


85. Celis JE, Gromov P, Cabezón T, Moreira JM, Friis E, Jirström K, Llombart-Bosch A, Timmermans-Wielenga V, Rank F, Gromova I: 15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma. Mol Cell Proteomics; 2008 Oct;7(10):1795-809
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma.
  • The remaining 10% include rarer types such as tubular, cribriform, mucinous, papillary, medullary, metaplastic, and apocrine breast carcinomas.
  • An additional subclass termed "molecular apocrine" has recently been described, but these lesions did not exhibit all the histopathological features of classical invasive apocrine carcinomas (IACs).
  • By comparing the protein expression profiles of apocrine macrocysts and non-malignant breast epithelial tissue we have previously reported the identification of a few proteins that are specifically expressed by benign apocrine lesions as well as by the few IACs that were available to us at the time.
  • Here we reiterate our strategy to reveal apocrine cell markers and present novel data, based on the analysis of a considerably larger number of samples, establishing that IACs correspond to a distinct molecular subtype of breast carcinomas characterized by the expression of 15-prostaglandin dehydrogenase alone or in combination with a novel form of acyl-CoA synthetase medium-chain family member 1 (ACSM1).
  • [MeSH-major] Apocrine Glands / enzymology. Apocrine Glands / pathology. Breast Neoplasms / classification. Breast Neoplasms / enzymology. Coenzyme A Ligases / metabolism. Hydroxyprostaglandin Dehydrogenases / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18632593.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.- / Hydroxyprostaglandin Dehydrogenases; EC 1.1.1.141 / 15-hydroxyprostaglandin dehydrogenase; EC 6.2.1.- / ACSM1 protein, human; EC 6.2.1.- / Coenzyme A Ligases
  •  go-up   go-down


86. Banneau G, Guedj M, MacGrogan G, de Mascarel I, Velasco V, Schiappa R, Bonadona V, David A, Dugast C, Gilbert-Dussardier B, Ingster O, Vabres P, Caux F, de Reynies A, Iggo R, Sevenet N, Bonnet F, Longy M: Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Res; 2010;12(4):R63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations.
  • INTRODUCTION: Breast carcinoma is the main malignant tumor occurring in patients with Cowden disease, a cancer-prone syndrome caused by germline mutation of the tumor suppressor gene PTEN characterized by the occurrence throughout life of hyperplastic, hamartomatous and malignant growths affecting various organs.
  • The gene expression profile of the Cowden tumors shows considerable overlap with that of a breast cancer subgroup known as molecular apocrine breast carcinoma, which is suspected to have increased androgenic signaling and shows frequent ERBB2 amplification in sporadic tumors.
  • The histological and immunohistochemical study showed that several cases had apocrine histological features and expressed GGT1, which is a potential new marker for apocrine breast carcinoma.
  • CONCLUSIONS: These data suggest that activation of the ERBB2-PI3K-AKT pathway by loss of PTEN at early stages of tumorigenesis promotes the formation of breast tumors with apocrine features.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] J Mol Endocrinol. 2003 Aug;31(1):169-83 [12914534.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] PLoS Biol. 2004 Feb;2(2):E7 [14737219.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):355-8 [15188009.001]
  • [Cites] Mol Endocrinol. 2004 Oct;18(10):2409-23 [15205473.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Am J Pathol. 1983 Feb;110(2):105-12 [6130702.001]
  • [Cites] Clin Genet. 1986 Mar;29(3):222-33 [3698331.001]
  • [Cites] Nat Genet. 1996 May;13(1):114-6 [8673088.001]
  • [Cites] Hum Pathol. 1998 Jan;29(1):47-53 [9445133.001]
  • [Cites] Hum Mol Genet. 1998 Mar;7(3):507-15 [9467011.001]
  • [Cites] Exp Dermatol. 1998 Dec;7(6):380-90 [9858141.001]
  • [Cites] Int J Cancer. 1999 Apr 20;84(2):150-4 [10096247.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):517-27 [15542435.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4660-71 [15897907.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2390-8 [16425225.001]
  • [Cites] BMC Genomics. 2006;7:96 [16643655.001]
  • [Cites] Oncogene. 2006 Jun 29;25(28):3994-4008 [16491124.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):560-9 [16899776.001]
  • [Cites] Bioinformatics. 2006 Sep 1;22(17):2066-73 [16820431.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):395-402 [17936563.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):102-7 [18066063.001]
  • [Cites] Histopathology. 2008 Jan;52(1):3-10 [18171412.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2122-31 [18381417.001]
  • [Cites] Neoplasia. 2008 Jun;10(6):542-8 [18516291.001]
  • [Cites] Breast Cancer Res. 2008;10(6):R101 [19055754.001]
  • [Cites] BMC Bioinformatics. 2009;10:84 [19291295.001]
  • [Cites] Nat Med. 2009 Aug;15(8):907-13 [19648928.001]
  • [Cites] Breast Cancer Res. 2009;11(4):R47 [19589159.001]
  • [Cites] Mod Pathol. 2010 May;23(5):644-53 [20208479.001]
  • [Cites] Mol Oncol. 2009 Jun;3(3):220-37 [19393583.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2760-3 [10850409.001]
  • [Cites] Hum Mutat. 2000;16(2):109-22 [10923032.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Curr Biol. 2001 May 15;11(10):764-8 [11378386.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8933-8 [12853564.001]
  • (PMID = 20712882.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.3.2.2 / gamma-Glutamyltransferase; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC2949656
  •  go-up   go-down


87. Wahl CE, Todd DH, Binder SW, Cassarino DS: Apocrine hidradenocarcinoma showing Paget's disease and mucinous metaplasia. J Cutan Pathol; 2009 May;36(5):582-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine hidradenocarcinoma showing Paget's disease and mucinous metaplasia.
  • [MeSH-major] Apocrine Glands / pathology. Carcinoma, Skin Appendage / pathology. Mucins / metabolism. Paget Disease, Extramammary / pathology. Sweat Gland Neoplasms / pathology

  • Genetic Alliance. consumer health - Hidradenocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19476529.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-7; 0 / Mucin-1; 0 / Mucins
  •  go-up   go-down


88. Fernandez-Flores A: Toker cell related to the folliculo-sebaceous-apocrine unit: a study of horizontal sections of the nipple. Rom J Morphol Embryol; 2008;49(3):339-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toker cell related to the folliculo-sebaceous-apocrine unit: a study of horizontal sections of the nipple.
  • MATERIAL AND METHODS: We have studied horizontal sections of the nipple in 10 cases from mastectomy specimens due to ductal carcinoma.
  • [MeSH-major] Apocrine Glands / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Nipples / pathology. Sebaceous Glands / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758638.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-7
  •  go-up   go-down


89. Constantinou C, Widom K, Desantis J, Obmann M: Hidradenitis suppurativa complicated by squamous cell carcinoma. Am Surg; 2008 Dec;74(12):1177-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hidradenitis suppurativa complicated by squamous cell carcinoma.
  • Hidradenitis suppurativa (HS) is a chronic inflammatory condition affecting the apocrine glands of the axilla, groin, and perianal region.
  • Although it is a common condition, it is rarely associated with squamous cell carcinoma (SCC).
  • Approximately half of the patients succumbed to their disease, and the grade of carcinoma was the only predictor of mortality.
  • Although the development of carcinoma is an uncommon event in HS, the consequences can be devastating with mortality approaching 50 per cent.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Hidradenitis Suppurativa / complications. Peritoneal Neoplasms / complications. Skin Neoplasms / complications


90. Kazakov DV, Kutzner H, Mukensnabl P, Michal M: Low-grade adnexal carcinoma of the skin with multidirectional (glandular, trichoblastomatous, spiradenocylindromatous) differentiation. Am J Dermatopathol; 2006 Aug;28(4):341-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade adnexal carcinoma of the skin with multidirectional (glandular, trichoblastomatous, spiradenocylindromatous) differentiation.
  • The conjoint occurrence of follicular, sebaceous, or apocrine differentiations in a cutaneous adnexal neoplasm is a known event, more often encountered in benign neoplasms, whereas reports of cutaneous malignant adnexal tumors with bilineage or trilineage differentiation are few.
  • We classified this tumor as a well-differentiated adnexal carcinoma demonstrating combined follicular and apocrine differentiation.
  • It differs from previously published cases of malignant adnexal tumors with multidirectional differentiation and further exemplifies the spectrum of diversity encountered in malignant proliferations with differentiation toward the folliculosebaceous-apocrine unit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871040.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Bahrami S, Malone JC, Lear S, Martin AW: CD10 expression in cutaneous adnexal neoplasms and a potential role for differentiating cutaneous metastatic renal cell carcinoma. Arch Pathol Lab Med; 2006 Sep;130(9):1315-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 expression in cutaneous adnexal neoplasms and a potential role for differentiating cutaneous metastatic renal cell carcinoma.
  • CONTEXT: Recent investigations have demonstrated the utility of CD10 as a marker for renal cell carcinoma (RCC).
  • OBJECTIVE: To determine CD10 expression in a variety of adnexal lesions and to determine the diagnostic utility of CD10 in an immunohistochemical panel differentiating metastatic cutaneous renal cell carcinoma from cutaneous adnexal neoplasms.
  • DESIGN: We studied 57 primary adnexal neoplasms of eccrine (n = 31), apocrine (n = 16), and sebaceous (n = 10) differentiation as well as normal skin (n = 3) and RCC metastatic to the skin (n = 4).
  • RESULTS: Two (6.5%) of 31 eccrine, 1 (6%) of 16 apocrine, and 4 (40%) of 10 sebaceous neoplasms demonstrated CD10 immunopositivity.
  • CD10 expression was significant for eccrine and apocrine neoplasms (P < .001) compared to metastatic RCC, but not for sebaceous neoplasms (P = .08).
  • CONCLUSION: Based on these results, CD10 is a useful additional immunostain for the discrimination of RCC metastatic to the skin and cutaneous adnexal neoplasms with eccrine and apocrine differentiation, but not with sebaceous differentiation.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Neprilysin / analysis. Skin Neoplasms / secondary
  • [MeSH-minor] Antigens, CD / analysis. Apocrine Glands / pathology. Diagnosis, Differential. Eccrine Glands / pathology. Humans. Immunohistochemistry. Sebaceous Glands / pathology. Skin / cytology. Skin / immunology. Skin / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16948517.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


92. Kavand S, Cassarino DS: "Squamoid eccrine ductal carcinoma": an unusual low-grade case with follicular differentiation. Are these tumors squamoid variants of microcystic adnexal carcinoma? Am J Dermatopathol; 2009 Dec;31(8):849-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Squamoid eccrine ductal carcinoma": an unusual low-grade case with follicular differentiation. Are these tumors squamoid variants of microcystic adnexal carcinoma?
  • Squamoid eccrine ductal carcinoma is a rare primary cutaneous tumor exhibiting both squamous and adnexal ductal differentiation.
  • The cell of origin of these tumors is unknown, and they have been classified both as variants of cutaneous squamous cell carcinoma and as a type of eccrine carcinoma.
  • We postulate that these tumors may be closely related to microcystic adnexal carcinoma and similarly show differentiation along both follicular and ductal lines, likely indicating folliculosebaceous-apocrine, rather than eccrine, origin or differentiation.
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Carcinoma, Squamous Cell / pathology. Eccrine Glands / pathology. Hair Follicle / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19786851.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Gutermuth J, Audring H, Voit C, Haas N: Primary carcinoma of ectopic axillary breast tissue. J Eur Acad Dermatol Venereol; 2006 Feb;20(2):217-21
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoma of ectopic axillary breast tissue.
  • Although the same pathology occurs in both eutopic and ectopic breast tissue, primary carcinoma of ectopic breast tissue has been reported only in a small number of cases.
  • Histological diagnosis can also be delayed if ectopic breast tissue is not present or screened for in the biopsy specimens as apocrine glands of the breast and skin, respectively, exhibit striking similarities and immunohistochemistry is of limited help.
  • Diagnostic delay is demonstrated by the case of a 56-year-old patient who underwent a series of four surgical excisions of a primary ectopic breast carcinoma and developed local lymph node metastasis until treatment with tamoxifen was started.
  • As two-thirds of reported cases of primary ectopic breast carcinoma arose within the axillae, this case underlines the importance of a search for ectopic breast tissue in the context of axillary ductal carcinoma.
  • [MeSH-major] Axilla. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Choristoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16441639.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


94. Iqbal J, He G, Biesecker LG, Rosen P, Duray PH, Schwartzentruber D, Beg M, Kahn E: Morphological characterization of the breast in Proteus syndrome complicated by ductal carcinoma in situ. Ann Clin Lab Sci; 2006;36(4):469-74
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological characterization of the breast in Proteus syndrome complicated by ductal carcinoma in situ.
  • Proteus syndrome (PS) is a severe, variable, and rare disorder with asymmetric and disproportionate overgrowth of body parts, cerebriform connective tissue nevi, epidermal nevi, dysregulated adipose tissue, and vascular malformations.
  • We report the first case of ductal carcinoma in situ (DCIS) in a 28-yr-old woman with PS who underwent a mastectomy for asymmetric overgrowth.
  • The former consisted of multiple intraductal papillomas and low-grade intraductal papillary, solid, and cribriform carcinoma.
  • The non-neoplastic changes were characterized by cysts of various sizes, lined by cuboidal or apocrine cells, focally with epithelial papillary proliferation; the lumens contained eosinophilic, mucicarmine-positive, and PAS-positive material.
  • The carcinoma was positive for ER, PR, CK7, and MIB-1 (40%), and negative for p53 and CK20 staining.
  • This case highlights the difficulty of recognizing small foci of carcinoma in an asymmetrical overgrowth of the breast in a young woman with PS.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Proteus Syndrome / pathology

  • Genetic Alliance. consumer health - Proteus syndrome.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127737.001).
  • [ISSN] 0091-7370
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


95. Fischer S, Breuninger H, Metzler G, Hoffmann J: Microcystic adnexal carcinoma: an often misdiagnosed, locally aggressive growing skin tumor. J Craniofac Surg; 2005 Jan;16(1):53-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adnexal carcinoma: an often misdiagnosed, locally aggressive growing skin tumor.
  • Microcystic adnexal carcinoma (MAC) belongs to the spectrum of locally aggressive adnexal carcinomas and most commonly occurs in the head and neck region.
  • Recently it has been proposed that MAC is an apocrine tumor.
  • Previous histopathologic diagnoses were squamous cell carcinoma and desmoplastic trichoepithelioma.
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Facial Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasms, Basal Cell / pathology

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15699645.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Ben Hassouna J, Damak T, Ben Slama A, Chargui R, Ben Dhiab T, Khomsi F, Gamoud A, Boussen H, Rahal K: Breast carcinoma arising within fibroadenomas. Report of four observations. Tunis Med; 2007 Oct;85(10):891-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast carcinoma arising within fibroadenomas. Report of four observations.
  • The incidence of a carcinoma within adenofibromas is estimated at 0.1 to 0.3%.
  • AIM: The purpose of this study was to evaluate the outcome of patients with breast carcinoma arising within adenofibroma and to determine the clinical characteristics and the prognosis of this rare entity.
  • In two cases, fibroadenomas was complex, containing cysts, adenosis and apocrine metaplasia.
  • [MeSH-major] Adenofibroma / pathology. Breast Neoplasms / pathology. Carcinoma / pathology. Cell Transformation, Neoplastic / pathology
  • [MeSH-minor] Adult. Breast Cyst / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Node Excision. Mastectomy. Metaplasia. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236815.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


97. Alessi E, Venegoni L, Fanoni D, Berti E: Cytokeratin profile in basal cell carcinoma. Am J Dermatopathol; 2008 Jun;30(3):249-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin profile in basal cell carcinoma.
  • Origin of basal cell carcinoma (BCC) is still unclear.
  • The study suggests a tumorous differentiation toward follicular outer root sheath cells and, in most cases, also toward the glandular components of the pilosebaceous-apocrine unit.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Basal Cell / metabolism. Keratins / metabolism. Skin Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18496426.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


98. Monaco SE, Dabbs DJ, Kanbour-Shakir A: Pleomorphic lobular carcinoma in pleural fluid: diagnostic pitfall for atypical mesothelial cells. Diagn Cytopathol; 2008 Sep;36(9):657-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic lobular carcinoma in pleural fluid: diagnostic pitfall for atypical mesothelial cells.
  • Pleomorphic lobular carcinoma (PLC) is a subtype of infiltrating lobular carcinoma because of its dyscohesiveness, linear infiltration pattern, and lack of membranous E-cadherin staining.
  • However, it differs from classic lobular carcinoma because of its high-grade cytology and more aggressive clinical behavior.
  • In breast fine-needle aspiration biopsies, PLC can be confused with invasive ductal carcinoma, particularly the apocrine variant.
  • However, the frequent apocrine features seen in this variant of breast carcinoma can cause nonspecific immunohistochemical positivity that may make the interpretation difficult.
  • This is the first report illustrating the cytopathology and immunohistochemical findings of pleomorphic lobular carcinoma in body cavity fluid cytology.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / pathology. Diagnostic Errors. Epithelium / pathology. Pleural Effusion / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18677762.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins
  •  go-up   go-down


99. Ben AJ, Bouasker I, Najah H, Zribi H, Bedoui R, Guesmi F, Hani MA, Nouira R, Zoghlami A, Najah N: Squamous cell carcinoma arising in Verneuil's disease. Tunis Med; 2008 Feb;86(2):169-70
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma arising in Verneuil's disease.
  • BACKGROUND: Verneuil's disease or hidradenitis suppurativa is a chronic suppurative, and cicatricial inflammatory disease, mainly affecting apocrine-bearing area of the skin.
  • Squamous cell carcinoma is an uncommon but a frightening complication of hidradenitis suppurativa.
  • AIM: To report a new case of squamous cell carcinoma arising in Verneuil's disease.
  • CASE REPORT: We reported a case of 60 year old man with a 30 years history of hidradenitis suppurativa in which squamous cell carcinoma arise.
  • CONCLUSION: Squamous cell carcinoma is an uncommon complication of hidradenitis suppurativa.
  • [MeSH-major] Anus Neoplasms / complications. Carcinoma, Squamous Cell / complications. Hidradenitis Suppurativa / complications. Skin Neoplasms / complications


100. Barré C, Lorenzato M, Bourdat B, Quéreux C, Durlach A: [Vulvar invasive squamous cell carcinoma and hidradenoma papilliferum. Case report]. Gynecol Obstet Fertil; 2007 Sep;35(9):776-9
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vulvar invasive squamous cell carcinoma and hidradenoma papilliferum. Case report].
  • We report a case of a vulvar invasive squamous cell carcinoma associated to a benign tumor with apocrine differenciation, the hidradenoma papilliferum, infiltrated by the carcinoma.
  • [MeSH-major] Adenoma, Sweat Gland / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Vulvar Neoplasms / secondary

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17766164.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down






Advertisement